Stockwinners Market Radar for May 11, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:33 EDT Enviva Partners director buys $994.5K in common stock - In a regulatory filing, Enviva Partners disclosed that its director John BumGarner bought 13.6K shares of common stock on May 9th in a total transaction size of $994.5K.

20:29 EDT Cathie Wood's ARK Investment bought 563.3K shares of Velo3D today

19:37 EDT Cardinal Health awarded $2.25B Defense Department contract modification - Cardinal Health has been awarded a maximum $2,250,000,000 modification exercising the second 30-month option period of a 30-month base contract SPE2DV-17-D0001 with three 30-month option periods for worldwide ordering and distribution of consumable, commercial, brand name and generic medical surgical supplies.

18:03 EDT Fossil cuts FY22 revenue growth view to flat to 3% from up 2%-6% - Fossil states: "The Company is updating its guidance for full year 2022 to reflect the current estimated impact of foreign currency translation, as well as COVID-19-related restrictions in China and geopolitical uncertainty in Europe on its international business. For fiscal year 2022, the Company now expects worldwide net sales growth of approximately flat to 3% versus prior guidance of 2% to 6%. This updated guidance includes an estimated foreign currency negative impact of 350 basis points, which compares to our prior estimate of 250 basis points for the full year. The Company anticipates that the impact of foreign currency translation will be most acute in the second and third quarters, with an estimated negative impact to net sales of 500 basis points. Updated net sales guidance for 2022 also includes an estimated impact of 150 basis points due to slowed revenue growth, primarily in our international markets. The Company is reducing adjusted operating margin(1) guidance by 50 basis points for the full year and now expects adjusted operating margin of 5.5% to 6.5% compared to prior guidance of 6.0% to 7.0%."

17:50 EDT XP Inc. authorizes share repurchase program for up to R$1B - XP Inc. has approved a share repurchase program under which XP may repurchase up to the amount in dollars equivalent to R$1.0B of its outstanding Class A common shares in the open market, over a period beginning on May 12th 2022 continuing until the earlier of the completion of the repurchase or May 12th 2023, depending upon market conditions. XP expects to utilize its existing cash to fund repurchases made under the repurchase program. The repurchase program does not obligate XP to acquire any specific number of shares in any period, and may be expanded, extended, modified or discontinued at any time.

17:40 EDT Ramaco Resources sees 2H22 results 'stronger' than 1H22 - "Quarterly production of 666,000 tons came in slightly ahead of budget. The company anticipates an increase in second quarter of 2022 results due to improving rail service. In addition, the company expects second half of 2022 results to be stronger than the first half of 2022. This is on the back of production increases mainly at the Berwind Mining Complex, in-line with our previously announced growth strategy, as well as lower cash costs per ton due to the anticipated startup of our Berwind Preparation Plant this summer, as well as a meaningful reduction in coal royalty costs resulting from the Ramaco Coal acquisition."

17:34 EDT Beyond Meat says taking measures to lower cash consumption

17:28 EDT Beyond Meat sees FY22 CapEx roughly $100M - Sees accelerated year-over-year revenue growth in 2H22. Sees Q1 margins being low point in FY22. Sees FY22 CapEx roughly $100M.

17:16 EDT Pan American Silver backs 2022 production view - Sees 2022 production of 19.0-20.5 Moz .silver, 550-605 koz. gold, 35-40 kt, 15-17 kt lead and 5.5-6.5 kt copper. Sees 2022 CapEx $280.0M-$305.0M.

17:11 EDT SeaWorld announces $250M share repurchase program

17:08 EDT Dutch Bros falls 34% to $22.75 after Q1 earnings miss

17:05 EDT CME Group CEO to appear at House panel hearing to review FTX proposal - CME Group Chairman and Chief Executive Officer Terry Duffy will appear at a hearing of the House Agriculture Committee on Thursday, May 12 to review an FTX proposal to launch an altered clearing model that could inject significant systemic risk into the U.S. financial system. "FTX's proposal is glaringly deficient and poses significant risk to market stability and market participants," Duffy said. "FTX proposes to implement a 'risk management light' clearing regime that would significantly increase market risks by potentially removing up to $170 billion of loss-absorbing capital from the cleared derivatives market, eliminating standard credit checks, and destroying risk management incentives by limiting capital requirements and mutualized risk. Under false claims of 'innovation,' FTX's proposal is nothing more than cost-cutting measures that would come at the expense of risk management best practices, market integrity, customer safety and, ultimately, financial stability."

17:01 EDT Lam Research announces $5B share repurchase program - Lam Research announced that its Board of Directors approved a $5B share repurchase authorization and a quarterly dividend of $1.50 per share of common stock. The company is authorized to repurchase up to $5B of common stock; this authorization supplements the remaining balances from any prior authorizations. Repurchases may be made through both public market and private transactions and may include the use of derivative contracts and structured share repurchase agreements. This repurchase program has no termination date and may be suspended or discontinued at any time. The dividend payment will be made July 6 to holders of record on June 15.

17:00 EDT Applovin trading resumes

16:56 EDT Disney CFO says continue to be pleased with demand at domestic parks - CFO Christine McCarthy says: "We continue to be pleased with the overall demand and attendance trends at our domestic parks. In fact, there were many days in the quarter where we saw demand exceed 2019 levels. However, we are continuing to control attendance through our reservation system with an eye on delivering a quality guest experience. As Bob mentioned earlier, per capita guest spending at our domestic parks increased by over 40% versus Q2 of fiscal 2019 and by 20% versus Q2 of fiscal 2021 with increases across the board on admissions, food and beverage and merchandise. Looking ahead to the third quarter. Our forward-looking demand pipeline at both Walt Disney World and Disneyland remains robust. And while attendance from international visitation is still in the early days of recovery, we are beginning to see some improvements. We are also thrilled that as of the end of March, all of our domestic resorts are now open, a major milestone as we continue to move through the impacts of the pandemic."

16:42 EDT Disney CEO says domestic parks grew per capita spending by over 40% vs. 2019 - CEO Bob Chapek says: "Domestic parks were a standout. They continue to fire on all cylinders, powered by strong demand coupled with customized and personalized guest experience enhancements that grew per capita spending by more than 40% versus 2019. Response to next-generation storytelling like Star Wars: Galactic Starcruiser has been phenomenal. In fact, guest ratings for this immersive experience, which opened March 1, are incredibly high and in line with our best-in-class offerings. Demand is strong, and we expect 100% utilization through the end of Q3." Comments taken from Q2 earnings conference call.

16:33 EDT BioCardia announces upcoming milestones - BCDA-01: Data Safety Monitoring Board review in the CardiAMP Cell Therapy Heart Failure Trial in Q3 2022. BCDA-02: CardiAMP Chronic Myocardial Ischemia Phase III pivotal trial roll-in cohort safety data in 2022. BCDA-03: IND acceptance of Phase I/II program of our allogeneic Neurokinin-1 Receptor Positive Mesenchymal Stem Cells for the treatment of ischemic heart failure, intended initially for those patients excluded from BCDA-01 in Q4 2022.BCDA-04: treatment of the first patient in our allogeneic NK1R+ MSC Phase I/II program for the treatment of ARDS resulting from COVID-19 in Q3 2022.

16:33 EDT Neuronetics extends commercial partnership with Transformations Care Network - Neuronetics announced an extended commercial partnership with Transformations Care Network, one of the nation's largest mental healthcare providers. Under the agreement, the Transformations Care Network will continue to expand upon its multi-state footprint of NeuroStar systems.

16:32 EDT KBR signs MoU with indigenous service provider JLB Yaran - KBR has signed a Memorandum of Understanding - MoU - with JLB Yaran that aims to enhance KBR's engagement with Australian First Nations communities and businesses. The agreement was signed at the 2022 Indo Pacific Conference in Sydney Australia. Under the non-binding agreement signed on Gadigal land, and witnessed by First Nations Elder Aunty Mary Doctor, KBR will collaborate with JLB Yaran to help recruit, connect and engage with First Nations peoples for multiple opportunities in locations across Australia. This will integrate JLB Yaran into KBR's wider technical support network. JLB-Yaran is an Indigenous and veteran-owned professional service provider. The signing of this MoU with JLB Yaran forms part of KBR Australia's Reconciliation Action Plan.

16:31 EDT Univar announces partnership with Motive Energy - Univar Solutions announced it will install 1020kW of solar capacity and an ESS with total energy capacity of 375kW/753kWh at its City of Commerce, CA facility in partnership with Motive Energy. This partnership marks a further investment by Univar Solutions in on-site renewable energy generation capacity, having recently completed solar projects at other global facilities in Europe and Latin America. The installation will significantly reduce the non-renewable energy usage and emissions of Univar Solutions' City of Commerce facility, one of the company's largest locations, through a custom solar and energy storage solution. The project will remove more than 1,300 tons of carbon dioxide from the environment per year, equivalent to removing 259 cars from the road or the electricity usage of 217 homes annually. This change is one more step toward achieving the company's long-term Environment, Social, and Governance goal of 20% absolute reduction of Scope 1 and 2 carbon dioxide emissions by 2025.

16:28 EDT Victory Capital reports AUM of $166B as of April 30, 2022 - Victory Capital Holdings reported assets under management of $166B as of April 30, 2022.

16:27 EDT Thorne HealthTech's blood sample collection device shows efficacy in study - Thorne HealthTech shared the results of a large-scale surveillance study conducted by the Medical Research Council Epidemiology Unit, University of Cambridge, to assess the prevalence of previous infection with COVID-19 using remote blood samples collected with the novel patient-administered OneDraw Blood Collection Device. 99.9% of the samples taken with the OneDraw device received by the laboratory were successfully processed. Over the 12-month study period, 4,000 U.K. participants collected a total of more than 10,000 blood samples remotely for repeated COVID-19 serologic testing. In the device feasibility study of 21 participants, participant acceptability was high, with 76% of participants preferring the OneDraw device over other blood collection methods. Results were published in the Journal of Telemedicine and Telecare on May 10. The OneDraw device is already cleared by the FDA as a Class II medical device and has a CE mark for the supervised use by health-care professionals to collect blood samples for the quantitative measurement of HbA1c for monitoring the long-term control of blood sugar in individuals with diabetes. Thorne HealthTech is currently studying additional applications of the OneDraw device, including the use of its new plasma separation cartridge. Thorne also plans to pilot the OneDraw device in its new Thorne Lab clinic.

16:25 EDT Sierra Wireless trading halted, news pending

16:24 EDT Sonos introduces Sonos Voice Control - Sonos introduced Sonos Voice Control, a first voice experience created purely for listening on Sonos. "Sonos is committed to delivering new experiences that effortlessly connect listeners to the content they love." said Joseph Dureau, Vice President, Voice Experience, Sonos. "One of the most natural ways to connect to your music is with your voice, but when we speak to our customers, we hear that privacy concerns mean many are choosing not to use voice control. Created purely for listening on Sonos and designed with privacy at its core, Sonos Voice control delivers the Sonos app experience using only your voice." Sonos Voice Control works on every voice-capable Sonos speaker, processing requests entirely on the device. No audio or transcript is sent to the cloud, stored, listened to or read by anyone. Available on new voice capable products and as a free update for existing customers, Sonos Voice Control is compatible with Sonos Radio, Apple Music, Amazon Music, Deezer, and Pandora at launch. More services and markets will follow.

16:20 EDT Myomo says continue to expect product revenue growth in 2022 - Myomo states: "The Company continues to believe its existing cash is sufficient to fund operations for at least the next 12 months. As the growing pipeline of MyoPro candidates converts into orders, we continue to expect year-over-year product revenue growth in 2022. Assuming receipt of the final payment of the license fee from our joint venture partner in China, $1.7 million of license revenue is expected to be recorded in the second quarter. Second quarter product revenues will reflect how much of the roughly $6.0 million of potential revenue in backlog we are able to recognize, along with our ability to generate new fill orders from the O&P, VA and international channels. We are diligently working to grow the pipeline while deploying creative ways to adapt to a changing marketing environment."

16:15 EDT Curtiss-Wright raises quarterly dividend 6% to 19c per share - Curtiss-Wright announced that the Board of Directors declared a 6% increase in the quarterly dividend to 19c per share, payable July 1, 2022 to stockholders of record as of June 17, 2022. "Curtiss-Wright remains committed to driving long-term shareholder value through a disciplined and balanced capital allocation strategy that consists of pursuing strategic acquisitions, reinvesting in our business to drive organic growth, and returning capital to our shareholders through share repurchase and dividend distributions," said Lynn M. Bamford, President and CEO of Curtiss-Wright Corporation. "We believe in steadily increasing our dividend in alignment with our long-term sales growth, and this recent increase reflects our Board of Directors' confidence in the Company's strong financial position while also allowing us to provide a consistent return to our shareholders."

16:14 EDT Exagen announces new PLA code, Medicare pricing for AVISA Lupus test - Exagen announced that Medicare Administrative Contractor Noridian has provided pricing for AVISE Lupus. Noridian's decision to price AVISE Lupus follows the approval by the American Medical Association CPT Editorial Panel of Proprietary Laboratory Code code 0312U for AVISE Lupus. The PLA code has an effective date of April 1, 2022. Noridian's pricing of AVISE Lupus along with AMA CPT's issuance of PLA Code 0312U both reflect the proprietary and novel aspects of AVISE Lupus which combine Cell-Bound Complement Activation Products along with an algorithmic SLE-likelihood assessment to aid providers in the evaluation of suspected SLE patients.

16:13 EDT Original Bark Company names Cindy Gustafson as Chief Marketing Officer - BARK "announced the appointment of Cindy Gustafson as Chief Marketing Officer. In this role, Ms. Gustafson will spearhead BARK's marketing organization and is responsible for developing and executing strategies that enhance the BARK brand and drive growth across the Company's key initiatives. She is based in New York and reports to BARK's Co-Founder, Executive Chairman, and Chief Executive Officer, Matt Meeker."

16:12 EDT Salarius completes pre-IND meeting process with FDA for SP-3164 - Salarius Pharmaceuticals announced the successful completion of its pre-IND meeting process with the FDA for SP-3164. SP-3164 is a next-generation targeted protein degrader that induces selective elimination of cancer-causing proteins. Salarius is developing SP-3164 as a potential treatment for hematological cancers and solid tumors. Through the pre-IND meeting process, Salarius obtained valuable FDA input that provided clarity on preclinical, clinical, and other regulatory matters for preparing and submitting an IND. Salarius is planning to submit an IND in 2023 and, upon receiving IND activation from the FDA, initiate the first clinical trial that same year.

16:11 EDT Rivian Automotive still sees FY production 25,000 vehicles

16:09 EDT Dutch Bros sees Q2 same shop sales flat to slightly negative - Total shop openings are expected to be at least 30, of which nearly all shops will be company-operated. Same shop sales are estimated to be flat to slightly negative as we face macro-economic headwinds impacting consumer discretionary income and gas prices. April same shop sales were (3.7)% in 2022 compared to 22.6% in 2021.

16:07 EDT Manning & Napier reports preliminary AUM $19.6B as of April 30 - Compared with $20.6B at March 31.

16:04 EDT Acorda Therapeutics, Biopas agree to commercialize INBRIJA in Latin America - Acorda Therapeutics "announced that they have entered into distribution and supply agreements to commercialize INBRIJA(R) in Latin America. INBRIJA is indicated in the United States for the intermittent treatment of episodic motor fluctuations in adult patients with Parkinson's disease (PD) treated with a levodopa/dopa-decarboxylase inhibitor. Under the terms of the agreements, Acorda will receive a significant, double-digit, tiered percentage of the selling price of INBRIJA in Latin America in exchange for supply of the product. Acorda will also receive sales-based milestones. Biopas will have the exclusive distribution rights to INBRIJA in nine countries within Latin America, including Brazil and Mexico. According to current population estimates, there are at least 400,000 people living with Parkinson's disease in Latin America1. Biopas plans on seeking marketing authorization in all countries to make Inbrija available for patients as quickly as possible."

15:19 EDT Google announces plans for physical store in Brooklyn - David Williams, Director, Retail Operations, at Google stated in a blog post: "A year ago, we opened the doors to Google's first-ever physical retail store in New York City. Since opening this flagship store in the iconic Chelsea neighborhood, we've heard how useful it is to try out our products in person - like giving the Pixel 6 Pro a spin or listening to a YouTube playlist on Nest Audio. Now, we're bringing this experience to even more New Yorkers. Today, we're announcing our plans to open our second physical store in Williamsburg, Brooklyn. The Google Store Williamsburg will be the first of our 'neighborhood stores,' offering similar hands-on experiences with our products and services as our flagship store, but in a more intimate setting that celebrates the unique neighborhood we're in. We'll start welcoming customers to our new location at 134 N 6th Street on June 16."

15:14 EDT Google unveils Google Pixel Watch, Anrdoid tablet at I/O - In a blog post, Alphabet's Google said that at its I/O event, it gave a preview of its new Google Pixel Watch, the first watch the company has built "inside and out." The device has a bold circular, domed design, a tactile crown, recycled stainless steel and customizable bands that easily attach. "With this watch, you'll get the new Wear OS by Google experience and Fitbit's industry-leading health and fitness tools - right on your wrist," the company said. "Google Pixel Watch is a natural extension of the Pixel family, providing help whenever and wherever you need it. It will be available this fall, and we'll share more details in the coming months." In addition, Google previewed its Pixel 7 phones, which are coming this fall, and its Android tablet, powered by Google Tensor. "Built to be the perfect companion for your Pixel phone, our tablet will blend into your day-to-day routine and help connect the moments you're on the go with the moments you're at home," the company said. "We hope to have more to share here in 2023, so stay tuned." Reference Link

14:15 EDT North American rail traffic fell 1.9% for the week ending May 7 - The Association of American Railroads, AAR, reported U.S. rail traffic for the week ending May 7. For this week, total U.S. weekly rail traffic was 504,927 carloads and intermodal units, down 3.5% compared with the same week last year. Total carloads for the week ending May 7 were 231,737 carloads, down 1.9% compared with the same week in 2021, while U.S. weekly intermodal volume was 273,190 containers and trailers, down 4.9% compared to 2021. Three of the 10 carload commodity groups posted an increase compared with the same week in 2021. They were motor vehicles and parts, up 3,071 carloads, to 14,400; nonmetallic minerals, up 1,671 carloads, to 33,952; and coal, up 522 carloads, to 63,281. Commodity groups that posted decreases compared with the same week in 2021 included metallic ores and metals, down 4,195 carloads, to 19,315; grain, down 2,813 carloads, to 22,402; and petroleum and petroleum products, down 1,177 carloads, to 8,940. North American rail volume for the week ending May 7 on 12 reporting U.S., Canadian and Mexican railroads totaled 329,158 carloads, down 0.5% compared with the same week last year, and 367,244 intermodal units, down 3.1 percent compared with last year. Total combined weekly rail traffic in North America was 696,402 carloads and intermodal units, down 1.9%. Publicly traded companies in the space include CSX (CSX), Canadian National (CNI), Canadian Pacific (CP), Kansas City Southern (KSU), Norfolk Southern (NSC), Union Pacific (UNP), Trinity Industries (TRN), Greenbrier (GBX), FreightCar America (RAIL), Wabtec (WAB), Berkshire Hathaway ( BRK.A, BRK.B) and GATX (GATX). Reference Link

13:41 EDT Volkswagen Group to launch all-electric pick-up and 'rugged' SUV in U.S - "The vehicles will be designed, engineered, and manufactured in the U.S. for American customers. To this end, a separate, independent company will be established in the U.S. this year as the Volkswagen Group (VLKAY;VWAGY)moves the strong iconic U.S.-brand Scout into the electric vehicle space. The first prototypes are to be unveiled next year, and production is scheduled to start in 2026. The electrified Scout brand will be built upon a new technical platform concept which brings new pickup and RUV credibility beyond the existing Volkswagen Group portfolio. Herbert Diess, CEO Volkswagen AG: "After Volkswagen's successful turnaround in the U.S., we are now taking the opportunity to further strengthen our position in one of the most significant growth markets for EVs. Electrification provides a historic opportunity to enter the highly attractive pick-up and R-SUV segment as a Group, underscoring our ambition to become a relevant player in the U.S. market." Success in the R-SUV & pick-up segments is a key lever to increasing profitability in the U.S. and achieving the targeted market share of ten percent. The Volkswagen Group is thus continuing to systematically expand its presence in one of the most significant global growth markets. Arno Antlitz, CFO Volkswagen AG: "The company we will establish this year will be a separate unit and brand within the Volkswagen Group to be managed independently. This aligns with the new Group steering model - small units that act agilely and have access to our tech platforms to leverage synergies," said the company in a statement. Competing companies include Rivian (RIVN), Workhorse (WKHS) Tesla (TSLA), GM (GM) and Ford (F). Reference Link

13:32 EDT Zynerba presents long-term safety, efficacy data of Zygel - Zynerba Pharmaceuticals is presenting an oral podium presentation at the International Society for Autism Research Annual Meeting, being held both in-person and virtually May 11-14, 2022, from Austin, TX. The presentation titled, "Long-Term Safety and Sustained Efficacy of ZYN002 Cannabidiol Transdermal Gel in Children and Adolescents with Fragile X Syndrome," includes data from 240 patients and demonstrates the long-term safety and efficacy of Zygel in children and adolescents with FXS. The study includes patients who entered the trial from two completed trials with Zygel: CONNECT-FX, a randomized, double-blind, placebo-controlled Phase 3 trial, and FAB-C, the initial open-label Phase 2 trial in FXS. The efficacy data were evaluated through 15 months of treatment and demonstrated improvements in both ABC-CFXS Social Avoidance and Irritability subscales. Patients with complete methylation of their FMR1 gene who completed CONNECT-FX and matched the primary efficacy population in the ongoing confirmatory RECONNECT trial achieved and maintained clinically meaningful change in ABC-CFXS Social Avoidance, and demonstrated similar improvements in ABC-CFXS Irritability subscale scores. These finding support the design enhancements that were made for RECONNECT. Zygel was well tolerated in patients, with a median duration of exposure of 16 months. Adverse events potentially related to Zygel were reported in 12.9% of patients; the most common reported in 6.7% of patients was application site pain which resolved quickly and was mild in the majority of cases.

13:25 EDT Occidental CFO says 'reasonable to expect' share repurchases to start in Q2 - Occidental Petroleum CFO Robert Peterson stated on the company's earnings call: "On our last call, we detailed our near-term debt reduction targets, including repaying $5 billion of debt and reducing net debt to $20 billion... Repaying $3.3 billion of debt in the first quarter was accomplished through a combination of a $2.9 billion tender offer, exercising the call provision on a note and open market repurchases. Following quarter end, we retired approximately $300 million in additional debt in open market repurchases, lowering gross debt to approximately $24.9 billion, which is a balance today. It is reasonable to expect that we near-term debt targets and then initiate our share repurchase program during the second quarter. Once we complete our near-term debt reduction target and repurchased $3 billion of shares, we will continue to allocate free cash flow to repaying debt as we lower gross debt to the high teens and billions. We believe reducing debt to this level will speed our return to investment grade and better position us to sustain a greater dividend at lower prices. When we reach this stage, we intend to transition from proactively reducing debt to primarily addressing maturities as they come due... Our consistently strong operational results in combination with the current commodity price environment are driving improved profitability on top of our already robust free cash flow generation. In the first quarter, we announced an adjusted profit of $2.12 per diluted share, our highest adjusted core EPS in over a decade, and a reported profit of $4.65 per diluted share... Given current commodity price expectations, we now expect to exhaust our U.S. net operating losses and most of our general business credit carryforwards this year. However, the NOLs and credits that we currently have remaining are expected to limit the amount of cash taxes paid this year... The increase in commodity prices certainly benefited us during the quarter, as demonstrated by our strong earnings and free cash flow generation. The commodity price environment improvement compared to the previous quarter also resulted in higher accounts receivable balances, which contributed to a negative working capital change. Negative working capital change was also driven by typical first quarter payments such as semi-annual interest payments, annual property tax payments and payments under compensation plan. As was the case in 2021, we see the potential for the working capital change to partially reverse over the remainder of the year if commodity prices are stable. And due to payments accrued during the year being made in subsequent first quarter. We are pleased to be able to update our full year guidance for Midstream and OxyChem, reflecting strong first quarter performance and improved market conditions. Our revised full year guidance for OxyChem now includes the expectation of a fourth consecutive record for quarterly earnings in the second quarter. We recognize the possibility of softer product prices later in the year, but still expect the third and fourth quarters to be exceptionally strong by historical standards... While our company-wide full year guidance is unchanged, as Vicki mentioned, we have included a 6,000 BOE per day downward adjustment to our full year international guidance, reflecting the impact of higher oil prices and our production sharing contracts. Our original budget included a forecast of $73 for Brent, while our revised guidance reflects a Brent average price of $95 for 2022. Inclusive of these activity changes, our 2022 capital guidance remains at $3.9 billion to $4.3 billion. We mentioned on our last call that our 2022 capital guidance incorporates approximately $250 million of inflation compared to 2021. The cost of materials and services necessary for operations, especially onshore in the United States has continued to increase. We are working to offset inflationary pressures through additional efficiency. But if price increases continue, we may spin near the top end of our capital guidance this year."

13:08 EDT Blue Water Vaccines Inc trading halted, volatility trading pause

13:02 EDT Blue Water announces expanded license agreement with St. Jude - Blue Water Vaccines announced an expanded license agreement has been signed with St. Jude Children's Research Hospital. Through research funded by Blue Water Vaccines, St. Jude designed genetic constructs to express bacterial proteins on the surface of Streptococcus pneumoniae. Blue Water Vaccines originally licensed patent rights from St. Jude in order to develop a live attenuated bacterial vaccine for acute otitis media caused by Streptococcus pneumoniae colonization in the middle ear cavity. Researchers at St. Jude have expanded on this research and identified a potential platform for vaccine creation by presenting additional antigens on the surface of S. pneumoniae, potentially allowing for protection against multiple infectious diseases. Preliminary data for this platform shows protection against S. pneumoniae and additional expressed antigens, including non-typeable Haemophilus influenzae, which represents another major cause of AOM.

12:17 EDT Cummins, Daimler Truck North America collaborate for hydrogen fuel cell trucks - Cummins and Daimler Truck North America are collaborating to upfit and validate Freightliner Cascadia trucks with a Cummins hydrogen fuel cell powertrain for use in North America. Freightliner will leverage Cummins' fourth generation fuel cell powertrain, which provides improved power density, efficiency and durability. The joint effort will support both organizations' goals to reduce emissions across product offerings and operations. Upon successful validation, the companies intend to have initial units available in 2024 for selected customers.

12:00 EDT Fiverr falls -20.6% - Fiverr is down -20.6%, or -$8.41 to $32.46.

12:00 EDT Unity Software falls -32.2% - Unity Software is down -32.2%, or -$15.52 to $32.61.

12:00 EDT H&R Block rises 17.7% - H&R Block is up 17.7%, or $4.20 to $27.97.

11:56 EDT Phillips 66 increases quarterly dividend 5% to 97c per share - The board of directors of Phillips 66 has declared a quarterly dividend of 97 cents per share on Phillips 66 common stock, representing a 5% increase. The dividend is payable on June 1, 2022, to shareholders of record as of the close of business on May 23, 2022.

11:47 EDT Rio Tinto starts tellurium production at Kennecott - Rio Tinto has started producing tellurium at its Kennecott copper operation in Utah. The tellurium will be refined in North America by 5N Plus, a leading global producer of specialty semiconductors and performance materials, under a commercial agreement between 5N Plus and Rio Tinto. The refined tellurium will primarily be supplied to First Solar, the only American company among the world's ten largest solar manufacturers, under an existing supply contract between 5N Plus and First Solar. 5N Plus will also use the tellurium to manufacture ultra-high purity semiconductor materials at its facility in St. George, Utah, to serve the security and medical imaging markets. Approximately 20 tons of tellurium will be produced per year through a new $2.9M circuit built at the Kennecott refinery. This valuable material is recovered from by-product streams generated during the copper refining process, reducing the amount of waste that needs to be treated and discarded as mine tailings.

11:38 EDT Sinclair Broadcast names Ryan Moore CRO, SVP of digital sales and sports - Sinclair Broadcast Group announced Ryan Moore has been named Chief Revenue Officer/SVP of Digital Sales and Sports. Moore was previously the company's Senior Vice President of Digital Sales, a position he has held since 2019. In addition to continuing oversight for all broadcast digital sales and Compulse, Sinclair's marketing technology and managed services company, Moore will add oversight of revenue and sales strategy for Tennis, Stadium, and Bally Sports.

11:07 EDT Southwest chooses Viasat's in-flight connectivity for aircraft deliveries - Viasat, Inc. (VSAT) announced Southwest Airlines (LUV) selected the Company's next generation Ka-band satellite in-flight connectivity system to be factory-installed on all new aircraft deliveries, starting this fall. The company said, "By selecting Viasat's industry-leading solution for its new aircraft, Southwest Airlines will provide customers enhanced internet capabilities while onboard, including the ability to stream content and entertainment, watch live television, and access social media platforms and productivity applications on any internet-ready device, gate-to-gate. Streaming-capable Wi-Fi requires a fast and robust data connection - especially to deliver high quality service on all connected devices while in-flight, regardless of how many passengers are using the system."

10:57 EDT Huadi International Group Company Ltd trading resumes

10:45 EDT Renren trading resumes

10:30 EDT Flora Growth launches Vessel in Canada, signs deal with Ontario Cannabis Store - Flora Growth Corp. announced its Vessel brand secured meaningful penetration in Canada via an approved listing on the Ontario Cannabis Store. Additionally, Vessel announced it has launched its Canadian direct-to-consumer online store, www.vesselbrand.ca to service customers directly across the country. Vessel will mark the first commercial entry for Flora Growth's product portfolio into Canada. Vessel's product will be available direct-to-consumer at vesselbrand.ca and at select retailers across the U.S. and Canada.

10:26 EDT Qiagen to acquire 96% majority stake in BLIRT SA, terms not disclosed - QIAGEN announced that it has signed agreements to acquire a 96% majority ownership stake in BLIRT SA, a manufacturer of recombinant enzymes for the life science industry based in Gdansk, Poland. BLIRT develops, manufactures and commercializes standardized and customized solutions for proteins and enzymes as well as molecular biology reagents. Its offering includes proteins and enzymes that are critical to the life sciences industry and diagnostic kit manufacturers, especially for non-COVID-19 applications. BLIRT, founded in 1994 in Gdansk, Poland, has approximately 90 employees and generated 2021 sales of less than $10M. Under the terms of the agreement, QIAGEN has acquired more than 96% of the outstanding shares of BLIRT in transactions with a group of leading shareholders. QIAGEN intends to obtain full ownership of BLIRT, which will be fully consolidated by QIAGEN following the closing of the transaction in the second quarter of 2022. The acquisition of BLIRT does not have any material impact on QIAGEN's financial outlook for 2022, as announced on April 26, 2022.

10:24 EDT Boeing does not need to issue equity, tap credit lines, says CFO

10:14 EDT Boeing CFO: China close to clearing 737 Max

10:13 EDT Boeing looks to improve defense margins to low single digits, CFO says

10:06 EDT Tyson Foods offers Commute with Enterprise ride-share program for team members - Tyson Foods is helping its team members address the barriers of transportation through Commute with Enterprise, a growing ride-share program that provides team members with a low-cost way to commute to work. The relationship began last year and has grown to include 26 Tyson Foods facilities, helping more than 1,000 team members and saving an estimated 4 million commuter miles. Enterprise works with each location to develop a vanpooling plan, which involves grouping employees based on where they live and the shifts they work. Commute with Enterprise provides each group with a minivan, SUV or passenger van, along with maintenance and insurance, while the riders share responsibilities, such as taking turns driving. Participants can save money by sharing the cost of renting the vehicle and gas. On average, it costs between $15 and $25 per week to participate. Some plants are taking other measures to assist team members with transportation. For example, Tyson Foods' facility in Eagle Mountain, Utah, created a car purchasing program by providing team members with three installments of $500 to help them buy reliable transportation. Over the course of 90 days, $1,500 is paid directly to the dealership to support the purchase. Full-time and part-time hourly team members, management support and temporary hires are eligible for the program.

10:02 EDT Cinedigm says connected television advertising business grew over 192% in 2021 - Cinedigm announced that the company's connected television advertising business grew more than 192% in 2021, beating the overall industry's streaming growth rate by 236%. According to figures released last week by the Internet Advertising Bureau, connected TV spending increased to $15.2B, up 57% over 2020, one of the fastest year-over-year rises in the history of digital advertising. Cinedigm bested that growth rate by more than 236%, driven by the company's growth in viewership to more than 40 million monthly ad-based viewers across the company's 30 enthusiast streaming services.

10:00 EDT Fiverr falls -24.6% - Fiverr is down -24.6%, or -$10.07 to $30.80.

10:00 EDT Unity Software falls -35.0% - Unity Software is down -35.0%, or -$16.84 to $31.29.

10:00 EDT Endeavour Silver rises 18.4% - Endeavour Silver is up 18.4%, or 57c to $3.67.

09:55 EDT Unity Software trading resumes

09:48 EDT Swedish Match board recommends accepting Philip Morris takeover bid - Swedish Match (SWMAY) said its board recommends that its shareholders of accept the takeover offer made by Philip Morris Holland Holdings (PM). Philip Morris is offering SEK 106 per Swedish Match share in cash, which values the issued share capital of Swedish Match at approximately SEK 161.2B. The offer price represents a premium of 39% percent compared to the closing share price of SEK 76.06 on May 9. The acceptance period of the offer is expected to commence on or around June 23, and expire on or around September 30. Goldman Sachs has, in its capacity as financial adviser, provided an opinion to the board that the SEK 106 in cash per share is fair from a financial point of view to the shareholders. The board "believes that the terms of the Offer recognise Swedish Match's long-term growth prospects, taking into account the risks associated with the realisation of those prospects." Reference Link

09:47 EDT Fiverr falls -24.8% - Fiverr is down -24.8%, or -$10.15 to $30.72.

09:47 EDT Unity Software falls -35.3% - Unity Software is down -35.3%, or -$16.99 to $31.14.

09:47 EDT Danimer Scientific rises 16.0% - Danimer Scientific is up 16.0%, or 57c to $4.12.

09:42 EDT Carvana trading halted, volatility trading pause

09:40 EDT Urban Gro Inc trading resumes

09:37 EDT Rocket Companies trading resumes

09:37 EDT Olaplex Holdings trading resumes

09:32 EDT Rocket Companies trading halted, volatility trading pause

09:32 EDT Olaplex Holdings trading halted, volatility trading pause

09:28 EDT SilverBow Resources announces closing of SandPoint acquisition - SilverBow Resources announced that it has closed its previously announced acquisition of certain assets from SandPoint Operating, LLC, a subsidiary of SandPoint Resources . Purchase consideration due to the seller, subject to customary closing adjustments, was comprised of approximately $31 million in cash and 1.3 million shares of SilverBow's common stock. The cash portion of the purchase was funded with cash on hand and borrowings under the Company's revolving credit facility.

09:27 EDT Aurora, Covenant team to find ways to optimize Covenant long-haul operations - Aurora Innovation (AUR) and Covenant Logistics Group (CVLG) announced a collaboration to explore ways to optimize Covenant's long-haul operations with Aurora's autonomous trucking product. Covenant with Aurora's autonomous trucking product. The two companies will explore the integration and deployment of Aurora Horizon within Covenant's operations. Part of Covenant's diversified services is long-haul trucking, making the benefits of autonomous technology in its network especially attractive. A hybrid model that blends trucks driven by humans with trucks driven autonomously would allow Covenant to realize the best of both and potentially expand its business with a combination of rapid, high-efficiency autonomous transport on long-haul routes and flexible human navigation at the endpoints.

09:24 EDT Blue Apron unveils The Next Course strategy at Investor Day - Blue Apron hosted its inaugural Investor Day on May 10, 2022 at its fulfillment center in Linden, New Jersey. Management unveiled The Next Course strategy, and discussed the company's strategic plans and outlook relating to its business, including details on its path to achieve adjusted EBITDA profitability in 2023 and positive free cash flow in 2024. The company also provided greater visibility into its near-term financial and operational performance expectations and targets. The Next Course strategy outlines a path to sustainable growth, profitability and shareholder return. Blue Apron's long-term goal is for the company to be the first choice for consumers who seek out curated food experiences that meet the needs of their household and enhance their lives. The company plans to expand beyond traditional meal kit subscriptions, including building an ecosystem of partners that creates Better Living Through Better Food. Blue Apron identified three objectives it will simultaneously target to drive growth over the next three years: Curated Customer Experiences - Drive customer growth and expand market share in target segments by deepening engagement through an ecosystem of marketing, partnerships and new products. Scalable Platform - Optimize tech and operational infrastructure to deliver an agile, scalable and seamless e-commerce experience with subscription at its core. Sustainable Profit - Execute ESG initiatives that meet customer priorities, drive employee engagement and create shareholder value. Randy Greben, Blue Apron's CFO, discussed the company's 2022 financial outlook, identified new areas for growth, and reviewed the company's target of achieving adjusted EBITDA profitability in 2023 and positive free cash flow generation in 2024. Greben commented, "Our strengthened balance sheet positions us to execute against the next evolution of our strategic plan with targeted marketing spend, continued investment in product innovation, and the build out of other revenue streams via partnerships, add-ons and marketplace offerings. We believe we can not only make meaningful progress on our path to profitability, but can do so while staying true to our guiding principles to serve all of our stakeholders. We see our path to 2024 - with set goals of having at least 500,000 customers, at least $700 million in revenue, with adjusted EBITDA margins of more than 2% and positive cash flow generation. We are excited about our prospects and all the different areas of growth that we see available to us."

09:22 EDT CycleBar partners with CELSIUS 'to fuel riders across the country' - "CycleBar, the world's largest indoor cycling franchise, announced today it has partnered with Celsius Holdings, , making CELSIUS the official energy drink of CycleBar. Riders can now stay active and energized in and out of the CycleTheater with CELSIUS drinks available for purchase across CycleBar studios nationwide," the company said in a statement.

09:21 EDT Kohl's shareholders re-elect all directors at 2022 annual meeting - Kohl's Corporation announced that based on the preliminary vote count provided by its proxy solicitor following the Company's 2022 Annual Meeting of Shareholders, Kohl's shareholders have voted to re-elect all thirteen of its director nominees - Michael Bender, Peter Boneparth, Yael Cosset, Christine Day, Chuck Floyd, Michelle Gass, Margaret Jenkins, Thomas Kingsbury, Robbin Mitchell, Jonas Prising, John Schlifske, Adrianne Shapira, and Stephanie Streeter - to the Company's Board of Directors. "We would like to thank our shareholders for their support throughout this proxy contest," said Peter Boneparth, Chairman of the Board. "While we have had differences with Macellum, this Board is committed to serving the interests of all our shareholders. The Board remains focused on running a robust and intentional review of strategic alternatives while executing our strategy to drive shareholder value. We appreciate the feedback we have received from our shareholders over the past several months and look forward to engaging with them further. We are especially thankful to Kohl's associates, who have continued to execute on our strategy and focus on customers during this process. Kohl's has a bright future ahead." In addition to the re-election of directors, Kohl's shareholders also: Ratified the appointment of Ernst & Young as the Company's independent registered public accounting firm for fiscal year 2022; and Approved an advisory resolution on the compensation of the Company's named executive officers reported in the Company's 2022 proxy statement. The results announced are considered preliminary until final results are tabulated and certified by the independent Inspector of Elections.

09:20 EDT InfiniteWorld partners with Chibi Dinos to create Chibiverse - InfiniteWorld and Chibi Dinos are proud to announce the launch of the "Chibiverse." The Chibiverse is based on the original "Chibi Dinos," intellectual property composed of 10,000+ uniquely generated NFTs created by serial entrepreneur Sean Kelly. The companies said, "The Chibiverse includes one of the first Metaverse play-and-earn sports games in our ecosystem - a basketball game called Primal Hoop, along with its action-adventure game, Primal Pick'em, a first-of-its-kind sports predictor leveraging the Chibi Dinos NFTs, and Chibi Adventures, in which players can explore the planet, fight enemies, develop skills, and find rare items that can be bought and sold on the marketplace. In Primal Hoop, the Chibi Dinos all play on one of 10 different Dino-themed basketball teams captained by real-world professional NBA/WNBA players, including Terrance Mann, P.J. Washington, and more names to be announced too. Both Primal Hoop and Chibi Adventures have been developed by InfiniteWorld's gaming division."

09:15 EDT ServiceNow launches new solutions built on Now Platform - ServiceNow introduced three new solutions built on the Now Platform to help enterprises advance their digital transformation efforts. Service Operations Workspace, App Engine Management Center and Public Sector Digital Services work across organizations and within the public sector to digitize complex processes and accelerate productivity.Service Operations Workspace gives service desk agents and operations teams a single place to manage work, collaborate, and have shared visibility into issues. It includes a unified user experience for agents and operations teams to work on the same problem at the same time and solve issues faster. This helps reduce downtime, improve customer satisfaction, and increase productivity across multiple groups. App Engine Management Center unleashes co-innovation between business and IT with low-code app development governance. As the number of citizen developers creating low-code solutions grows, the role of IT must evolve to empower co-innovation at scale while maintaining governance protocols. AEMC is a turnkey low-code governance solution to successfully scale and safeguard app development across an organization with App Engine. Platform admins can set guardrails, apply standards, enable co-innovation between business and IT, and check for compliance in a single place without any friction. Additionally, AEMC helps centrally manage all aspects of low-code app dev, from app intake to collaboration requests, to pipeline monitoring and deployment tasks. ServiceNow has also published a new Citizen Development Center of Excellence website, making it easy for customers and prospects to find the content they need to build a successful citizen development program with App Engine. Public Sector Digital Services provides governments with a digital foundation to deliver consumer-grade experiences from request to resolution. For many people, requesting standard government services often requires visiting a local office, filling out paper forms, and submitting additional documentation, with poor visibility into the status of these requests. Within governments, fulfilling these requests can be slow and require personnel to navigate multiple aging systems and manual processes. Public Sector Digital Services provides out-of-the-box public sector data models and workflows to help governments speed innovation, deliver better experiences, and resolve requests faster. Constituents benefit from increased convenience, transparency, and responsiveness.

09:14 EDT Desktop Metal to showcase collection of 300+ 3D printed production parts - Desktop Metal announced it would display a historic collection of more than 300 3D printed production parts May 17-19 in Detroit at RAPID + TCT, North America's largest and most influential AM event, alongside production-capable printing platforms for metals, polymer, elastomers, ceramics, composites, and upcycled wood materials. Desktop Metal's parts and printer collection, which will greet attendees in Booth No. 3301 at the main entrance of the show, demonstrates how the AM industry stands ready to deliver on President Joe Biden's recently announced AM Forward initiative to accelerate the adoption of industrial 3D printing. Biden spoke in detail May 6 about the power of 3D printing to modernize the nation's manufacturing infrastructure and lower prices by producing high-demand parts locally with the technology.

09:12 EDT Cloudflare announces Cloudflare D1 - Cloudflare announced Cloudflare D1, a simple and instant serverless database. Cloudflare D1 will enable developers to start building database-backed applications using Cloudflare Workers with just a few clicks. Data will be stored close to where their users are, providing lightning fast performance without any of the complexities of installing or managing a traditional database.

09:09 EDT Walmart picks Citrix 'to underpin new era of work management' - Wrike, a work management platform, now part of Citrix (CTXS), announced that Walmart has expanded its Wrike instance outside of Walmart Canada. It now encompasses more than 1,000 new users across international teams, including Global Tax, Product, Walmart Health, and Walmart Realty. With the ability to bring cross-departmental work into a single digital workspace, Wrike is enabling Walmart to work as one and giving them a level of visibility into and control over projects and resources that they've never had before. In 2019, Walmart Canada deployed Wrike within their Continuous Improvement team to boost productivity and develop business recommendations for the Transportation department. Following the success of Wrike's integration, Walmart Canada implemented the work management platform into PMO, Strategy, Transportation, Supply Chain Planning, Logistics Operations, Supply Chain Reinvention/End to End, Marketing, and E-commerce Studio. With other areas of the business operating in different ways, however, there was a lack of standard processes across Walmart International. The organization set out to create a structure and foundation that would enable them to come together and take their business to the next level.

09:08 EDT Equitable launches partnership, program curriculum with Columbia University - Equitable has launched a unique partnership and program curriculum with Columbia University. The program invites financial professionals to study specific curriculum focused on holistic financial planning and coaching clients on fulfilling their life goals and dreams. Upon completion of the program, financial professionals gain a qualification called the Columbia University Holistic Financial Coach Credential.

09:07 EDT Easterly Government acquires NARA Federal Records Center in Colorado - Easterly Government Properties announced that it has acquired a 161,730 leased square foot National Archives and Record Administration Federal Records Center in the Denver metropolitan region. In connection with the acquisition, the Company issued to the seller 827,791 common units in its operating partnership. NARA - Broomfield, a build-to-suit warehouse constructed in 2012, is 100% leased to the General Services Administration on behalf of NARA pursuant to a 20-year lease, which does not expire until May 2032. NARA - Broomfield is one of 18 facilities strategically located throughout the country, and holds permanent and temporary records created by Federal agencies and courts across seven states. To ensure the preservation of these important documents, the facility was specifically constructed to the exact needs of the National Archives, providing for optimal environmental controls and to maintain certain set points for both temperature and humidity. With a professional staff of approximately 1,110 Federal employees, the FRC services approximately 13 million reference requests annually across all locations for nearly 400 Federal agency customers. The enduring nature of this mission necessitates physical storage and maintenance of highly important documents in optimal storage conditions throughout the United States.

09:06 EDT STMicroelectronics announces collaboration with Microsoft - STMicroelectronics (STM) has revealed details of its collaboration with Microsoft (MSFT), an ST Authorized partner, to strengthen the security of emerging Internet-of-Things applications. ST is integrating its ultra-low-power STM32U5 microcontrollers with Microsoft Azure RTOS & IoT Middleware and a certified secure implementation of Arm Trusted Firmware -M secure services for embedded systems.

09:05 EDT Trecora Resources to be acquired by affiliate of Balmoral Funds - Trecora Resources and an affiliate of Balmoral Funds, together with its consolidated subsidiaries, Balmoral, have entered into a definitive merger agreement pursuant to which Balmoral agreed to acquire Trecora for $9.81 per share in cash in a transaction that values the company at an enterprise value of $247M, which represents approximately 11.4x our 2021 adjusted EBITDA. TREC owns and operates a facility in southeast Texas which specializes in high purity hydrocarbons and other petrochemical manufacturing. TREC also owns and operates a leading manufacturer of specialty polyethylene waxes and provider of custom processing services located in the heart of the Petrochemical complex in Pasadena, Texas. In addition, TREC is a 35% owner of Al Masane Al Kobra Mining. Under the terms of the Merger Agreement, which has been approved by the Trecora Board, Balmoral will commence a tender offer to acquire all outstanding shares of Trecora's common stock, par value 10c per share for $9.81 per share in cash. The purchase price represents a 29.9% premium to Trecora's closing stock price on May 10. The closing of the transaction is subject to customary closing conditions, including the expiration or termination of certain regulatory periods and the tender of shares representing at least a majority of the Company's outstanding common stock to Balmoral, and is expected to close in Q3. Following the successful completion of the tender offer, Balmoral will acquire all remaining shares not tendered in the tender offer through a second-step merger at the same price. Upon completion of the transaction, Trecora will become a privately held company and shares of Trecora Common Stock will no longer be listed on any market.

09:05 EDT Iroquois: PharmaCyte Biotech has failed to create meaningful value for holders - Iroquois Capital Management, one of the largest shareholders of PharmaCyte Biotech, with beneficial ownership of approximately 5.1% of the outstanding common stock of the company, announced that it has delivered a letter to the company's Board of Directors. It stated, in part, "Iroquois Capital Management is one of the largest stockholders of PharmaCyte Biotech, with ownership of approximately 5.1% of the company's outstanding shares. We invested in Pharmacyte because of our belief in the promise of its proprietary cellulose-based live cell encapsulation technology known as 'Cell-in-a-Box' and the potential for its use as a platform upon which cellular therapies for several types of cancer and diabetes can be based upon. However, much to our disappointment, the Company has failed to create meaningful value for stockholders or articulate any plan to do so despite its envious assets and the patience its stockholders have extended to the Board of Directors of the company and management to date in connection with the development of its product portfolio. Iroquois has substantial experience and a successful track record of working constructively with the boards of directors and management teams of our portfolio companies to enhance stockholder value. Over the past six months, we have had multiple constructive discussions with the Chairman of the Board, Chief Executive Officer, President and General Counsel, Kenneth L. Waggoner. We are appreciative of our engagement with Mr. Waggoner to date, but with the company's stock price trading almost 50% lower than the price at which our initial investment was made in August 2021, and at a significant discount to the cash on Pharmacyte's books, we feel it is necessary at this time to raise our concerns directly to the Board as the stewards of stockholder capital." Reference Link

09:03 EDT O'Reilly Auto Parts expands Domo pact with five-year enterprise license - Domo (DOMO) announced that American retailer O'Reilly Auto Parts (ORLY)has signed a five-year renewal agreement and is expanding its current Domo relationship beyond store operations and loss prevention to unlock data value across its entire organization. "With Domo, we've improved the process of providing relevant and actionable information to our operators and decision makers, giving us greater agility and allowing us to better serve our customers. With Domo, we can better manage and deliver information to the entire O'Reilly organization faster and more efficiently, while maintaining strong governance and leveraging our existing data investments," said Jeff Lauro, SVP Information Technology, O'Reilly Auto Parts.

08:58 EDT Shutterstock acquires Pond5 for $210M in cash - Shutterstock announced the acquisition of Pond5, the world's largest video-first content marketplace for filmmakers, media organizations, and marketers worldwide. Pond5 is the world's leading online marketplace for royalty-free and editorial video, with customers including Netflix, Disney, NBC, BBC, Discovery Channel and The Wall Street Journal. Pond5's comprehensive collection includes 30 million licensable video clips, 1.6 million music tracks and 1.7 million sound effects assets. Transaction Highlights: Consideration for the transaction consists of $210 million of cash paid at closing. Further scales Shutterstock's video business and expands Shutterstock's editorial offering with unique and high-quality exclusive video content. Complementary customer base with powerful relationships with the world's largest media outlets, social media platforms, and OTT streaming companies. Maintaining 2022 revenue and adjusted EBITDA margin guidance. Immediately accretive to 2022 adjusted EBITDA, even after one-time transaction related costs.

08:56 EDT Cornerstone National Insurance implements Guidewire InsuranceNow - Cornerstone National Insurance Company and Guidewire announced that CNI has implemented Guidewire InsuranceNow to accelerate speed-to-market to quickly launch new products and drive business growth.

08:51 EDT Vinci Partners announces divestment in Pro Infusion - Vinci Partners announced that "Vinci Impacto e Retorno IV", or "VIR IV," the impact family of funds managed by Vinci Partners' Private Equity strategy, has entered into a definite agreement for the sale of its stake in Pro Infusion, a leading outsourcing company of pharmaceutical compounding services. VIR IV will sell its stake in Pro Infusion to Viveo Group, an ecosystem of companies specialized in each link of the health sector. Viveo Group is acquiring 100% of The Company. The transaction marks the first and full divestment by the Fund in less than two years after its investment.

08:48 EDT AbbVie's upadacitinib shows Crohn's Disease remission in Phase 3 study - AbbVie announced positive topline results from U-ENDURE, its Phase 3 maintenance study evaluating upadacitinib in adult patients with moderate to severe Crohn's disease who had an inadequate response or were intolerant to a conventional or biologic therapy. Results showed that more patients treated with either dose of upadacitinib achieved the co-primary endpoints of endoscopic response and clinical remission, as well as the secondary endpoint of endoscopic remission, at one year compared to placebo. Use of upadacitinib in Crohn's disease has not been evaluated by health authorities. Results from the U-ENDURE maintenance study, in addition to results from the U-EXCEED and U-EXCEL induction studies, will be included in future regulatory submissions. A significantly higher proportion of patients who received upadacitinib 15 mg or 30 mg achieved clinical remission per the CDAI at week 52: 37% and 48%, respectively, vs. 15% in the placebo group. 36% and 46% of patients who received upadacitinib 15 mg and 30 mg, respectively, achieved clinical remission at week 52 per SF/AP vs. 14% in the placebo group. The safety results of upadacitinib were generally consistent with the safety profile observed in the Phase 3 induction studies in Crohn's disease, as well as the known safety profile of upadacitinib. No deaths were reported throughout the study and no new safety risks were identified.

08:47 EDT Conduent selected to provide TPL Services to state health agencies - Conduent announced it has been selected as a qualified solutions provider by the National Association of State Procurement Officials, NASPO, ValuePoint cooperative purchasing program to deliver Third-Party Liability, TPL, Services to state health agencies. As part of this qualification, Conduent will be eligible to compete for upcoming solicitations, based on its expertise and interoperable, modular technology, to help multiple states' Medicaid programs accurately and efficiently solicit payments from third-party resources.

08:43 EDT Sky Technologies appoints Lance Shaner as chair of Hotel Advisory Board - SQL Technologies announced that renowned hotel entrepreneur Lance Shaner will Chair Sky's newly formed Hotel Advisory Board. Shaner serves as Chairman and CEO of Shaner Hotel Group. Chaired by Mr. Shaner, the Hotel Advisory Board is expected to assist in driving the adoption of the smart SkyPlug and related Sky Platform into lodging facilities including hotels, resorts, the growing vacation rental industry and apartment buildings.

08:40 EDT Banxa Holdings launches Fiat to NFT Checkout offering - BANXA Holdings announces the launch of its new product offering Fiat to NFT Checkout in partnership with leading non-fungible token marketplace Atomic Hub. With the rapid rise of the NFT consumer market over the last 12 months, this release positions Banxa to participate in the growing market, allowing its global partner network access to millions of end users looking to more easily purchase NFTs with credit cards.

08:38 EDT Vallon Pharmaceuticals reports issuance of Japanese patent for ADAIR - Vallon Pharmaceuticals announced that the Japan Patent Office has granted Patent No. 7054709 titled, "Abuse Deterrent Formulations of Amphetamine," covering ADAIR1, the Company's proprietary abuse-deterrent formulation of immediate-release dextroamphetamine. David Baker, President & CEO of Vallon commented, "The Japanese market is one of the fastest growing markets for prescription ADHD medications. Historically, there has been concern over the abuse potential of psychostimulants in Japan, however, this has begun to change in recent years with the introduction of several new products. As we continue to evaluate the best path forward for our novel abuse-deterrent formulation of dextroamphetamine, ADAIR, we are pleased to expand its global intellectual property portfolio. We are working to evaluate and unlock its potential and importantly, move toward potentially bringing a safe and effective option to ADHD patients in need." The new Japanese patent covers composition of matter and methods of manufacturing for ADAIR, with a base patent term extending until 2038. The design and development of an abuse-deterrent formulation involves the balance of limiting the potential for manipulation and abuse while maintaining acceptable dissolution rates and bioavailability. ADAIR was previously granted two patents in the United States with a base patent term extending until 2037, excluding patent term extensions and one patent in Europe with a base patent term extending until 2038.

08:37 EDT OSI Systems receives $12M contract for border security inspection systems - OSI Systems announced that its Security division was awarded a contract valued at approximately $12M by an international customer to provide multiple units of the Eagle P60 ZBx drive-through cargo and vehicle inspection system, optical under vehicle inspection system license plate and face capture system, and follow-on service and support. OSI Systems' Chairman and CEO, Deepak Chopra, stated, "We are pleased to receive this order and look forward to deploying our solutions to improve border security. In addition to the Eagle P60 ZBx, vehicle and passenger identification solutions from our recent acquisition were also purchased by the customer to support this security initiative."

08:37 EDT Miroculus to optimize NGS library preparation with Interpace, Twist - Interpace Biosciences (IDXG) has announced that in association with Miroculus, it will optimize next generation sequencing, NGS, library preparation utilizing its digital microfluidics, DMF, technology. Also working in conjunction with Miroculus and Interpace Biosciences will be Twist Bioscience Corporation (TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA. Interpace Diagnostics will utilize Twist Bioscience's chemistries for library preparation and hybridization capture for the automation of Interpace's custom NGS panels, and Miroculus's DMF instrument, the Miro Canvas, to enable low volume, accurate, and precise sample preparation for its genetic tests targeting specific markers in Endocrine and GI cancers. "It's an exciting time in diagnostic testing as new insights are unveiled every day that allow patients to be treated earlier in their cycle of disease. We are pleased to enable Interpace's deployment of clinical services with our flexible sample-to-sequencer NGS reagent workflow that improves the uniformity of their assays, thus reducing the cost of sequencing and the assay overall," commented Emily Leproust, Ph.D., CEO and Co-founder of Twist Bioscience.

08:36 EDT BioSig: PURE EP system has completed over 2,200 patient cases - To date, company's FDA 510(k) cleared PURE EP system has completed over 2,200 patient cases with 75 physicians at 17 hospitals across the United States, BioSig said in a statement. "We have made great strides on multiple fronts and felt it was an important time to communicate to our shareholders the strength of our business and the initiatives we are executing that have served as the foundation for our growth trajectory," said Kenneth L. Londoner, Chairman, and CEO of BioSig Technologies, Inc. "We strongly believe in the value of our technology and are now supported with both peer-reviewed clinical data and third-party economic data, proving the value of what we have built. We are eager to continue working on our new commercialization strategy, seeing the impact of our new NOVA-5 software has, and all our initiatives we are undertaking to drive shareholder value and expand PURE EP."

08:35 EDT Dyadic International announces research, license for animal-free ingredients - Dyadic International announced that it has entered into a Joint Development Agreement with a Global Food Ingredients Company to develop and manufacture a number of animal free ingredient products using the company's biotechnologies. Under the terms of the Agreement: The research project will be fully funded by the Global Food Ingredients Company up to EUR 3.6 million. Dyadic to develop its proprietary production cell lines for the manufacture of animal free ingredient product candidates. Dyadic will receive certain defined "Success Fees", upon reaching certain productivity and activity levels and milestones at different stages of the collaboration. Dyadic will receive a "Commercialization Fee" of low eight figures upon commercialization, and a royalty payment of low single digits based on commercial sales. "While our primary focus remains speeding the adoption of our C1 protein production platform for use in developing and manufacturing biopharmaceuticals, we believe that this strategic partnership demonstrates the company's ability to leverage its technologies by taking advantage of emerging market opportunities to enhance the value the company can bring to biomanufacturing," said Mark Emalfarb, Dyadic's President, and CEO.

08:35 EDT Heritage Cannabis expects production to begin at Missouri facility in Q3 - The company said, "Heritage has made significant progress on the licensed manufacturing facility build-out in support of the relationship with 3Fifteen Primo Cannabis in the state of Missouri. The Heritage team has progressed with establishing the biomass supply chain and is in the process of training staff for the facility. Production is expected to begin in Q3, with revenue from the sale of branded products to medical cannabis consumers in Missouri following shortly after."

08:34 EDT Heritage Cannabis provides update on flower, pre-rolls - The company said, "In 2021, Heritage launched into pre rolls and flower SKUs in multiple provinces with encouraging provincial orders. Already in a short time-frame, Heritage ranks #25 in pre-rolls and #45 in flower. Heritage continues to add new products including infused pre-rolls and blunts to the flower category, and with growing popularity is expected to take an increasing share of the largest cannabis product segment in the Canadian market."

08:32 EDT TTEC Holdings awarded contract with Georgia Technology Authority - TTEC company Avtex Solutions has been awarded a contract with Georgia Technology Authority - GTA - for Hosted Contact Center Services as part of their GTA Direct Program. Avtex will provide contact center services to local governments, agencies, and schools under this contract. The GTA Direct program provides a quick path to managed IT services from pre-qualified providers and makes those services available to Georgia agencies, local governments, colleges and universities, and boards of education statewide. Contracts for Hosted Contact Center Services provide Georgia state agencies and other public-sector entities with access to a choice of new technology solutions at competitive prices.

08:28 EDT Fiverr drops 12% to $36.00 after cutting FY22 guidance

08:26 EDT Moderna CFO Jorge Gomez departs, recently retired David Meline to continue role - Moderna (MRNA) announced that its recently appointed CFO Jorge Gomez, has departed the Company, effective immediately. The announcement follows the May 10 public disclosure by Mr. Gomez's former employer, Dentsply Sirona (XRAY) of an ongoing internal investigation into certain matters, including financial reporting. Moderna's recently retired CFO David Meline, will continue in his role of CFO as of May 11 while Moderna reopens its search for a new CFO.

08:23 EDT MariaDB announces database challenge on distributed SQL offerings - MariaDB Corporation announced a database challenge to any company evaluating distributed SQL offerings. Compare Xpand, MariaDB's distributed SQL database, in a proof of concept with another distributed SQL solution. If Xpand does not demonstrate better throughput and lower latency, MariaDB will donate $25K to either a nonprofit or to offset the infrastructure costs associated with running the test. The challenge applies to either Xpand deployed on a customer's hardware or cloud infrastructure, or Xpand deployed in the cloud on MariaDB SkySQL.

08:21 EDT Agoda announces partnership with Visa - Global travel platform Agoda announced its partnership with Visa (V) to offer interest-free credit card instalments across its booking platform. Agoda will be the first global Online Travel Agency to offer this payment option with Visa in the Asia Pacific region. These instalments can now be exclusively enjoyed by HSBC Bank Malaysia credit card holders. In the coming years, Visa and Agoda will progressively roll out this offering regionwide to locations like Australia, Hong Kong, Singapore, Thailand, Vietnam and Philippines, each with respective issuing banks. Agoda is part of Booking Holdings (BKNG).

08:20 EDT Lantheus announces updates to NCCN guidelines for PSMA PET imaging - Lantheus Holdings announced that both the National Comprehensive Cancer Network and the Society of Nuclear Medicine and Molecular Imaging have now updated their guidelines for the use of prostate specific membrane antigen positron emission tomography imaging. Both the NCCN guidelines and the SNMMI appropriate use criteria note that all approved PSMA PET imaging agents, including PYLARIFY, may be used for patient selection for PSMA-targeted radioligand therapy. "We are pleased that the NCCN and SNMMI have now both updated their guidelines to include PYLARIFY, the most widely adopted PSMA PET imaging agent, for patient selection for PSMA-targeted lutetium radioligand therapy," said Bela Denes, MD, Lantheus Vice President of Medical Affairs. "We believe this will increase the accessibility to PSMA-targeted therapeutics for patients with advanced disease and further validates the benefit and utility that PYLARIFY provides to the U.S. prostate cancer community."

08:20 EDT Aerojet Rocketdyne chairman says special meeting campaign 'a costly distraction' - Aerojet Rocketdyne Holdings Executive Chairman Warren Lichtenstein, who, collectively with his affiliates and the participants in his solicitation, owns approximately 5.2% of the Company's outstanding shares, commented on Eileen Drake's efforts to call a Special Meeting of Stockholders: "The campaign by Ms. Drake, General Kevin Chilton, General Lance Lord and Thomas Corcoran to call a Special Meeting is a costly distraction from the crux of this contest: which side possesses the credibility and strategic vision needed to properly run Aerojet and maximize value for all shareholders. Time and time again, Ms. Drake and her allies have misused shareholders' resources, taken self-serving steps and shown an utter lack of credibility. The attempted Special Meeting is nothing different - it is a dubious and desperate ploy to hold on to her position. Further, Ms. Drake lacks any real vision for the future of the Company and creating value for shareholders. Her faction's presentation released on May 10th is devoid of any forward-looking plans for the business and merely rehashes arguments she has used previously in an attempt to discredit me. In contrast, my proposed slate has put forth a detailed plan to maximize value for all shareholders. We have made - and continue to make - clear commitments that would enable the Company to hold its Annual Meeting of Stockholders within a short window after Ms. Drake's proposed Special Meeting would occur, at a time when shareholders will have the benefit of the evidence presented to the Delaware Court of Chancery in the trial of Ms. Drake for misuse of corporate resources. In our view, stockholders should have the opportunity to review and consider that evidence before deciding whether Ms. Drake is fit to continue to serve as CEO and as a director. We are fully aligned with the best interests of all shareholders and our primary goal is to ensure that they have the ability to make their voices heard at a proper and fair meeting."

08:19 EDT Neuronetics files lawsuit against Brainsway for unfair competition - Neuronetics (STIM) announced the filing of a federal lawsuit in the District of Delaware against Brainsway Ltd. (BWAY) and Brainsway USA Inc. for unfair competition under the Lanham Act and state law. In the litigation, the company asserts that, for commercial gain, Brainsway egregiously misrepresented efficacy data for the treatment of anxious depression with NeuroStar Advanced Therapy for Mental Health. Specifically, the company argues that Brainsway manipulated NeuroStar's effect size by presenting an endpoint representing an incomplete course of therapy. Brainsway then compared these results to inappropriately aggregated data from three disparate studies using Brainsway devices with effect sizes derived from full courses of therapy. The company alleges Brainsway's manipulated presentation of these results misled clinicians and patients about NeuroStar's efficacy. In the litigation, Neuronetics is seeking injunctive relief as well as monetary damages. "Neuronetics views strong, high-quality data as the cornerstone of driving TMS as a mainstream treatment for mental health disorders. We have made a significant investment to develop a robust body of clinical evidence and believe that we have the best data in the industry," said Keith J. Sullivan, President and CEO. He added, "We will vigorously defend against the mischaracterization of the efficacy of NeuroStar TMS, the damage it causes to our business and the confusion it causes medical professionals and their patients. We look forward to pursuing this case through the federal courts and to begin to correct this grievous mischaracterization of our efficacy data beginning later this week during the Clinical TMS Society annual meeting in Chicago."

08:18 EDT Dare Bioscience announces NIH grant award of $249,000 - Dare Bioscience announced a Notice of Award of a grant from the Eunice Kennedy Shriver National Institute of Child Health & Human Development, NICHD, of the National Institutes of Health, NIH, of approximately $249,000 to support end-user research, including surveys of approximately 1,000 women in the U.S. ages 18-44 years, to better understand women's preferences for a long-acting injectable contraceptive method. "The grant will enable Dare to better understand women's preferences, particularly with regard to the key features of LAI hormonal contraceptives," said David Friend, PhD, Chief Scientific Officer of Dare Bioscience. "The findings from this study will inform our target product profile and guide our development priorities for ADARE-204 and ADARE-214. We are excited to be working with the Population Council on this important initiative and we are grateful to NICHD for its commitment to advancing new programs that have the potential to address unmet needs and offer a better experience for women."

08:17 EDT Iterum reaches 'general alignment' with FDA on aspects of Phase 3 trial design - Iterum Therapeutics announced it met with the US Food and Drug Administration on May 5, 2022, to discuss its proposed plan to conduct one additional Phase 3 clinical trial to support the potential resubmission of the company's new drug application for oral sulopenem etzadroxil-probenecid for the treatment of uncomplicated urinary tract infections. "We are pleased to announce that we have reached general alignment with the FDA on key aspects of our proposed trial design to support the potential resubmission of the NDA for uUTI," said Corey Fishman, Chief Executive Officer. "We are designing this additional Phase 3 clinical trial as a non-inferiority trial comparing oral sulopenem and Augmentin for the treatment of uUTI in adult women. We intend to request an agreement with the FDA regarding the proposed protocol under the special protocol assessment process in the coming weeks and subject to finalization and receipt of the SPA agreement, we plan to initiate enrollment in the second half of 2022."

08:17 EDT HCI Group's Greenleaf Capital enters agreement to sell parcel for $13.4M - Greenleaf Capital, the real estate division of HCI Group, has entered into an agreement to sell one and a half acres of right-of-way in connection with a planned road improvement project. After transaction costs, Greenleaf expects to receive net proceeds of approximately $14.5M compared with a net book value of $1.1M. Following the sale, Greenleaf will retain an office building on six acres of land and expects to re-lease the property to a new tenant at a significant premium to existing rent. The sale is scheduled to close by the end of third quarter 2022.

08:15 EDT Edible Garden names Mathew McConnell, Tracy Nazzaro, Ryan Rogers to board - Edible Garden announced the appointment of three new independent members to the Company's board of directors as of May 4, 2022: Mathew McConnell, Tracy Nazzaro, and Ryan Rogers. McConnell has served as CEO of Marco Polo Securities since March 2020, while Nazzaro is presently the President, Chief Financial Officer and General Manager for Trader's Hill Farm and Rogers spent nearly two decades working in the food retail industry in merchandising, sales and sourcing positions.

08:14 EDT Harsco's Clean Earth announces Detroit TSDF earn drug distributor accreditation - Clean Earth, a division of Harsco Corporation, announces its treatment, storage and disposal facility, TSDF, in Detroit, MI has earned the Drug Distributor Accreditation, previously known as Verified-Accredited Wholesale Distributors Program, VAWD, from the National Association of Boards of Pharmacy. The accreditation allows the facility to expand the breadth of its reach nationwide, while confirming its distinguished status as a responsible handler of prescription drugs for destruction. With this accreditation, Clean Earth, and its Detroit TSDF will continue to play a pivotal role in preventing the diversion of pharmaceutical waste and safeguarding against improper drug disposal and the associated environmental implications.

08:13 EDT Kaltura announces expansion of virtual events platform - Kaltura announced the release of new capabilities to Kaltura Events, "empowering organizations of all sizes to automate event management for all of their internal company and external marketing events. Event organizers can now use Kaltura Events to create, manage, track and scale fully branded virtual and hybrid event experiences of any size and any kind, all in a single platform. Used by leading brands to power major events, creating uniquely branded experiences, Kaltura Events now offers a new approach to branded event automation, leveraging event templates that enable customers to power and measure all of their events at scale."

08:12 EDT Westrock Coffee achieves commitment to responsible source 100% of tea products - Westrock Coffee Holdings announced the successful achievement of its previously stated goal to responsibly source 100% of its tea globally. As of the end of 2021, Westrock Coffee's entire tea product supply is certified, further demonstrating its commitment to create responsible products and solutions that foster social equality, environmental resilience, and economic opportunity throughout the Company's supply chains. Westrock Coffee's vertically integrated systems and history of supporting the livelihoods of smallholder farmers around the world has led the Company to create transparent, digitally traceable supply chains from farm to final product for many of the world's most iconic brands. This affords Westrock Coffee's customers and farmer partners the assurance of a responsible supply chain, with sustainability as the ultimate goal. Westrock Coffee recently piloted its first digitally traceable tea supply chain from Argentina through its Farmer Direct Verified platform, opening the possibility for the Company's farmer partners and customers to be a part of its first transparent tea supply chain.

08:10 EDT TransAct Technologies gets 140 unit BOHA! WorkStation order - TransAct Technologies announced that it has secured its largest BOHA! WorkStation order yet, representing 140 units. The company expects to deploy all 140 WorkStations in the third quarter of 2022. The complete system deployment will initially include the BOHA! WorkStation, BOHA! Labeling software, proprietary BOHA! labels and service. TransAct estimates total annual recurring revenue per unit will be approximately $1,000 per year. BOHA! is the first single-vendor cloud-based enterprise system to combine applications for Food Safety, Date Code and Grab n' Go Labeling, Temperature Monitoring of Food and Equipment, Checklists & Task Management, Inventory Management, Timers, and Food Recall, in one integrated platform. Each BOHA! solution combines cloud-based SaaS applications with hardware and accessories to deliver superior results for critical back-of-house operations. BOHA! offers a one-stop solution for restaurants, convenience stores and food service companies to address their current back-of-house operating requirements while providing a future-ready platform capable of addressing back-of-house operations.

08:08 EDT Corbus Pharma's CRB-601 shows preclinical anti-tumor activity - Corbus Pharmaceuticals announced new preclinical data for CRB-601 being presented at the New York Academy of Sciences Frontiers in Cancer Immunotherapy Conference. The latest preclinical data for CRB-601 demonstrate its significant effects on inhibiting tumor growth as a single agent and in combination with anti-PD-1 treatment in the MC38 and EMT6 syngeneic tumor models. In addition, CRB-601 restores an anti-PD-1 effect in the 4T1 syngeneic tumor model. Collectively these data suggest that treatment with CRB-601 could overcome the immune excluded phenotype established in this model and enhance the efficacy of treatment with anti-PD-1 therapy. Additionally, tumor-bearing mice reinoculated with the same tumor cells showed no tumors formed after 30 days in this cohort of animals, whereas all the treatment naive control mice succumbed to the burden of tumor growth. These data illustrate that the combination treatment of CRB-601 + anti-PD-1 led to durable T-cell memory protection.Corbus is currently developing CRB-601 as a potential treatment for solid tumor cancers, and the program is advancing toward an IND submission in the first half of 2023.

08:06 EDT IBM, SAP announce expansion of technology partnership - IBM (IBM) and SAP (SAP) announced the latest milestone in their long-standing partnership as IBM undertakes one of the world's largest corporate transformation projects based on SAP ERP software, designed to fuel the company's growth and better support its clients. As part of the expanded partnership, IBM is migrating to SAP S/4HANA, SAP's next-generation ERP software, to perform work across more than 120 countries, 1,000 legal entities and numerous IBM businesses supporting software, hardware, consulting and finance. The project is focused on improving business processes with RISE with SAP S/4HANA Cloud, private edition, premium supplier option with IBM Consulting, and will ultimately move more than 375 TB of data to IBM Power on Red Hat Enterprise Linux on IBM Cloud. RISE with SAP brings together what businesses need to pursue their digital transformation objectives and accelerate their move to the cloud. Driven by the need to modernize processes and deliver better insights to support clients running in the cloud, RISE with SAP is helping IBM centralize and standardize data worldwide. With access to the SAP HANA database, data can be accessed in real time and shared more efficiently among business units and teams. The expanded partnership will also help with improved decision-making supported by AI and automated workflows. Once the transformation is completed, nearly all of IBM's $58B in revenue will flow through SAP software.

08:05 EDT Cocrystal Pharma sees completing CC-42344 Phase 1 study this year - "Among our goals this year is to complete the CC-42344 Phase 1 influenza study and to initiate two Phase 1 COVID-19 studies with CDI-45205 and a novel, broad-spectrum orally administered protease inhibitor designed and developed using our proprietary structure-based drug discovery platform technology," said James Martin, CFO and co-interim CEO. "We are well positioned to execute on these goals in the current challenging economic environment, given our clean capital structure and a cash balance we believe is sufficient to fund planned operations through 2023."

08:05 EDT Wolters Kluwer Compliance Solutions to host LEP banking webinar - Wolters Kluwer Compliance Solutions' Timothy Burniston, Senior Advisor, Regulatory Strategy, will lead a regulatory compliance webinar with moderator Darren Welch, Counsel, Skadden, Arps, Slate, Meagher & Flom LLP, "A Roadmap for Limited English Proficiency." The complimentary event will take place 2-3 pm EDT on Tuesday, May 24. Joining Burniston and Welch in this panel discussion are Sara Erickson, Vice President, Fair & Responsible Banking Program Manager, U.S. Bank, and Dave Rosamond, Executive Director and Assistant General Counsel, JPMorgan Chase & Co. Darren Welch will moderate the session. Serving banking customers in non-English languages is generally viewed as a positive development for all participants. However, there are many uncertainties for banks to consider in properly executing on an LEP strategy, including determining to what extent such services and product offerings can be operationalized. Session participants will review the requirements and risks around LEP offerings and then dive into some regulatory guidance issues and specific compliance measures related to non-English language support. This session will seek to answer financial institutions' most pressing questions around LEP product and service offerings.

08:04 EDT Check-Cap initiates trial of C-Scan at Mayo Clinic in Rochester Minnesota - Check-Cap announced the initiation of its U.S. pivotal trial of C-Scan at Mayo Clinic in Rochester Minnesota. The company has successfully obtained Institutional review board approval for the study and expects to promptly begin patient enrollment. Elizabeth Rajan, M.D., gastroenterologist, and professor of medicine at Mayo Clinic, will be the principal investigator of the study at this site.

08:03 EDT Health Catalyst acquires ARMUS, terms not disclosed - Health Catalyst announced that it has acquired ARMUS Corporation, a Silicon Valley-based clinical registry development and data management technology company. ARMUS provides data abstraction, data validation, data management, data submission, and data reporting services to support participation in clinical quality registries for healthcare institutions around the world, including health systems, payers, medical device companies, and premier medical societies.

08:03 EDT Absci sees adding at least eight new Active Programs for 2022 - Absci reiterates its guidance to add at least eight new Active Programs for 2022, representing 60% year-over-year growth. Absci maintains its full year 2022 guidance of expecting a net decrease in cash, cash equivalents, and restricted cash of approximately $120M, which includes one-time, time-based disbursements totaling $10.5M from restricted cash associated with the Denovium and Totient acquisitions.

08:02 EDT Regulus' IND application for RGLS8429 accepted by FDA - Regulus announced that the FDA has accepted its Investigational New Drug Application for RGLS8429 for the treatment of Autosomal Dominant Polycystic Kidney Disease - ADPKD -, enabling the company to initiate its planned Phase 1 clinical study of RGSL8429 in healthy volunteers. The company will conduct a Phase 1 single-ascending dose study in healthy volunteers to assess safety, tolerability and pharmacokinetics of RGLS8429. Following the SAD study, the company plans to initiate a Phase 1b multiple ascending dose study in adult patients with ADPKD to assess safety, tolerability and pharmacokinetics of RGLS8429, and to evaluate the efficacy of RGLS8429 treatment across three different dose levels including changes in polycystins, cystic kidney volume, and overall kidney function. ADPKD, caused by mutations in the PKD1 or PKD2 genes, is among the most common human monogenic disorders and a leading cause of end-stage renal disease. The disease is characterized by the development of multiple fluid filled cysts primarily in the kidneys, and to a lesser extent in the liver and other organs.

07:56 EDT ForgeRock introduces ForgeRock Autonomous Access - ForgeRock introduced ForgeRock Autonomous Access, a new solution that uses artificial intelligence to prevent identity-based cyber attacks and fraud. The new solution monitors login requests in real-time to block malicious attempts, adds authentication steps for anomalous behaviors, and streamlines access for known users.

07:52 EDT Ondas targets $20M in product bookings in 2022 - Ondas is reaffirming its financial and operational outlook for 2022. Ongoing investments in market expansion and deeper penetration of select verticals are expected to support commercial adoption of Ondas Networks' FullMAX wireless platform and additional installations of AR's Scout System in 2022. Ondas Networks will continue to focus on the greenfield 900 MHz network with North American Class I Rails. Ondas Networks expects bookings and revenue growth to accelerate as the Company moves through the year with a target of $20 million in product bookings in 2022. In addition, Ondas Networks expects to add an additional $3.5 million in product development programs with its partners in 2022. In the second quarter of 2022, Ondas Networks intends to continue building product inventory and increasing internal human resources to meet an expected increase in product demand for both North American Rail and International markets. Also, the Company expects American Robotics to secure and announce additional franchise customers for the Scout System in 2022. Throughout 2022, AR will continue to build inventory to meet this customer demand. In parallel, American Robotics will continue to invest in and scale its field service operations to create capacity to handle expanded drone deployments with existing customers and to support new customer activity. Scout System deployments will focus on a select group of blue-chip customers in the oil & gas, mining, bulk materials, and rail sectors in the coming quarters. AR is targeting 30 Scout Systems installed by year end 2022 allocated to 10 customer accounts, and its objective is to secure one or more customer reorders to begin fleet expansion. In parallel, American Robotics will continue to invest in data analytics products targeted at these customers and their respective markets. The Company's cash operating expenses are expected to be approximately $7.0 - $7.5 million in the second quarter and may trend up over the course of 2022. Cash operating expenses exclude non-cash expenses, such as stock-based compensation and amortization of intangible assets and goodwillThe Company expects bookings and revenue growth to fluctuate from quarter-to-quarter given the timing of development activity in front of the targeted commercial rollout for the Rail 900 MHz network, the multiple development projects planned with Siemens Mobility and the integration and scaling of American Robotics business.

07:49 EDT Switch jumps 8% to $33.20 after buyout offer from DigitalBridge, IFM

07:46 EDT Draganfly partners with Airworx Unmanned Solutions for 2022 SCPSUSS - Draganfly announces that the Company is partnering with Airworx Unmanned Solutions for the 2022 SC Public Safety Unmanned Systems Summit, SCPSUSS. The event is taking place at in Greenville, South Carolina from May 12-13, 2022. Draganfly will showcase how its Drone as First Responder, DFR, and AI Vital Intelligence platforms can assist a variety of law enforcement sectors. "Draganfly has a long and proud history of developing cutting-edge drone solutions, software, and AI systems that improve public safety," said Cameron Chell, President and CEO of Draganfly. "We look forward to working with Airworx, a leader in the field, and sharing how our DFR plus Vital Intelligence platforms can be used to help reduce response times, increase situational awareness and improve overall efficiency during critical missions."

07:45 EDT Switch to be taken private by DigitalBridge, IFM in $11B transaction - Switch (SWCH) announced it has entered into a definitive agreement with DigitalBridge Group (DBRG), under which DigitalBridge Partners II, the value-added digital infrastructure equity strategy of the investment management platform of DigitalBridge, and an affiliate of global infrastructure investor IFM Investors, will acquire all outstanding common shares of Switch for $34.25 per share in an all-cash transaction valued at approximately $11B, including the assumption of debt. The transaction, which was unanimously approved by a special committee of the Switch Board of Directors, is expected to close in the second half of 2022. The transaction is subject to approval by Switch stockholders and the satisfaction of other customary closing conditions. Upon completion of the transaction, Switch will no longer be traded or listed on any public securities exchange.

07:45 EDT Chicken Soup for the Soul Entertainment trading halted, news pending

07:43 EDT Switch to be taken private by DigitalBridge, IFM in $11B transaction

07:40 EDT Spark Power signs agreement with Leeward Renewable Energy - Spark Power Group announced the signing of a long-term operations & maintenance agreement between its solar O&M business and Leeward Renewable Energy, that directly provides O&M support for three of LRE's California solar facilities: Rabbitbrush Solar, Chaparral Solar and Willow Springs 3 Solar. LRE, a leading renewable energy company, contracted Spark Power to be the primary Solar O&M provider for the three solar energy facilities in Rosamond, California, which will have an aggregate capacity of approximately 274 MWAC. The Projects are expected to be operational by August 2022 and will also have co-located utility scale battery storage systems.

07:38 EDT Jumia Technologies shares first ESG report - Jumia released its first Environmental Social Governance Report outlining its ESG strategy alongside an overview of current sustainability practices at Jumia. The report draws on Jumia's 2021 non-financial data and provides disclosures in line with Sustainability Accounting Standards Board materiality topics for e-commerce entities as well as the UN Sustainable Development Goals. While recognising the importance of standard ESG focus areas, Jumia draws attention to the unique role that e-commerce plays in advancing more equal opportunities in Africa. As such the company has made its mission, "Leveraging technology to improve everyday lives in Africa," the first pillar of its sustainability strategy.

07:37 EDT AXA, Unilever, Tikehau Capital sign MOU to create impact fund - AXA (AXAHY), Unilever (UL), and Tikehau Capital have announced they have signed a Memorandum of Understanding outlining their ambition to create an impact fund dedicated to accelerating and scaling the regenerative agriculture transition. Together, agriculture, land use, and deforestation represent the second-largest source of greenhouse gases emissions globally and the primary driver of biodiversity loss. Regenerative agriculture practices can reverse this trend and play a crucial role in addressing climate change and environmental challenges. Healthy soils can sequestrate carbon, support biodiversity, preserve water, and improve the resilience of agricultural yields, bringing healthy food while ensuring a sustainable source of income for millions. The aim of the fund, which will be managed by Tikehau Capital, will be to promote regenerative agriculture practices by focusing on three core areas: Protecting soil health to enhance biodiversity, preserve water resource and help fight climate change; Contributing to the future supply of regenerative ingredients to meet the needs of a growing global population and consumer demand for increasingly sustainable products; Helping to unlock technological solutions that aim to accelerate the transition to regenerative agriculture. Leveraging on the international network of AXA, Unilever and Tikehau Capital, the fund is expected to be global. Impact objectives and measurement will be central to the way it operates and fully embedded in its investment strategy.

07:34 EDT CI Financial release historical results in new segmentation format - CI Financial released quarterly 2021 data in accordance with its new segment reporting. In addition, CI has provided information about the accounting presentation related to the establishment of CI Private Wealth in the U.S.

07:33 EDT JetBlue appoints Al Spencer as VP, controller - JetBlue (JBLU) announces the appointment of Al Spencer as the carrier's new vice president, controller. Spencer will oversee the company's corporate accounting, tax, payroll, accounts payable and fraud, and revenue accounting teams. He will report to Ursula Hurley, JetBlue's CFO. Spencer comes to JetBlue from Paris-based publicly traded gas manufacturer Air Liquide (AIQUY), where he served as deputy CFO North America and Corporate Controller since 2017.

07:33 EDT Monte Rosa Therapeutics sees submission of INDA for MRT-2359 in mid-2022 - Sees initiation of at least one additional lead optimization program expected in 2022.

07:31 EDT Evaxion Biotech sees cash, equivalents funding operations through next 12 months

07:28 EDT On24 announces availability of engagement, conversion data in HubSpot - ON24 announced the availability of engagement and conversation data from the ON24 platform in HubSpot. This builds upon the previous integration of ON24 registrant and attendee profiles, campaign information, and event details in HubSpot. In just under six months since ON24 was listed in the HubSpot App Marketplace, more than 75 customers have implemented ON24 with HubSpot. With ON24 first-person data and engagement insights now available in HubSpot, sales and marketing can uncover more opportunities to drive personalized interactions and better qualify leads for sales and marketing follow-up. ON24 and HubSpot are helping sales and marketing shift from manual handoffs to automating next best actions with prospects and customers. First-person engagement and intent data captured during ON24 digital experiences such as demo requests, meetings booked, content downloaded, poll responses, and questions asked automatically flow into HubSpot to inform and trigger actions for sales and marketing teams.

07:26 EDT On24 announces latest updates across ON24 platform - ON24 announced the latest innovations across the ON24 platform. Customers can enhance prospect and customer engagement, capture more audience insights, and deliver better personalized experiences with the following new products, features, and capabilities. New live engagement experience - Available now, ON24 Forums enables organizations to drive high-touch moderated discussions that deepen audience participation. Companies can create and scale fully branded, customized digital experiences that capture rich first-person insights, including executive engagement, focus groups, and expert-led trainings. Read the ON24 Forums press releasefor more information. Enhanced breakout rooms - NewON24 Breakouts capabilities allow attendees to raise their hands during breakouts; give marketers the ability configure how names are displayed, including anonymous attendees; enable recording and archiving of breakout discussions; and provide attendees engagement tools on their mobile devices. New capabilities in ON24 Breakouts are available now in ON24 Webcast Elite. Expanded chat capabilities - Available now, new features across the ON24 platform allow an unlimited number of attendees to chat during digital experiences as well as send direct messages to each other. Audiences can now react to messages, reply to specific chats, and send emojis. Moderators also have the control to delete messages. Account-based personalization - new account-based marketing capabilities across the ON24 platform enable sales and marketing to use first-party data and audience insights to dynamically personalize webinars, content hubs, and landing pages with logos, as well as content based on an individual's title, company, industry, and interests. Available now, sales and marketing can target individuals at specific companies through personalized messages and digital experiences. Read the account-based personalization press release for more information. Deliver hybrid virtual conferences - Hybrid event features in ON24 Virtual Conference allow audiences to choose a virtual or physical event experience when registering, as well as personalized QR codes to check-in each participant at the venue. Now customers have more choices to deliver hybrid event experiences with ON24 Virtual Conference or ON24 Webcast Elite. New hybrid event features are available now in ON24 Virtual Conference. New reporting across ON24 platform - ON24 Intelligence gives organizations more ways to track, analyze, and report on engagement. Securely share reports in ON24 Webcast Elite externally and monitor all access. Benchmark engagement performance against industry peers and similar use cases across all ON24 experiences. Monitor metrics for all categories in ON24 Engagement Hub, as well as track new buying signals and chat data. Track ON24 Forums and ON24 Go Live event engagement for each user on the prospect engagement profile. See the full list of URLs added to ON24 experiences and all clicks and views in one place. Get new audience reporting in ON24 Go Live and view first-party engagement details for every event and session. All reporting capabilities are available now.

07:24 EDT Five9 extends EMEA footprint with new data centers in Frankfurt and Amsterdam - Five9 announced the general availability of two data centers located in Frankfurt and Amsterdam. The data centers serve Five9 customers in the European Union Europe, the Middle East, and Africa, supporting the company's international growth and the desire for European customers to maintain data residency. "We are excited to see the growing demand for our cloud contact center solutions in Europe and the value our global data center footprint brings to Five9 customers," said Panos Kozanian, Five9 EVP of Cloud Operations. "The Frankfurt and Amsterdam data centers will help Five9 continue delivering the latest contact center and customer experience innovations to both European customers and multinational companies with a presence in both the US and EMEA."

07:22 EDT Medicenna Therapeutics presents Phase 1/2 ABILITY study data - Medicenna Therapeutics announced that clinical data from the Phase 1/2 ABILITY study of MDNA11, the company's long-acting IL-2 super-agonist, have been featured in a poster presentation at the 9th Annual Frontiers in Cancer Immunotherapy Meeting. The meeting, organized by the New York Academy of Sciences, is taking place both virtually and in-person from May 9 - 11, 2022. The presentation featured both, previously announced data from the ABILITY study's initial dose escalation cohorts showing dose-dependent stimulation of anti-cancer immune cells with MDNA11 treatment, as well as new pharmacokinetic and pharmacodynamic analyses from the first 8 patients with treatment refractory solid tumors. Key findings from the new analyses include: MDNA11 treatment led to a dose-dependent expansion of cancer fighting lymphocytes and no significant increases in eosinophil count when compared to baseline. Extremely high eosinophil count is associated with severe toxicity and is a known side effect of high-dose recombinant human IL-2. MDNA11 treatment potently activated anti-cancer CD8+ T cells by increasing (a) their population by greater than3-fold, and (b) boosting their activation as shown by increase in both, CD25+ and ICOS+ CD8+ T cells. Unlike IL-2, MDNA11 did not induce an increase in ICOS+ Treg cells. ICOS+ Treg cells are highly immunosuppressive and associated with lack of response to high dose IL-2 immunotherapy.

07:21 EDT NFI Group to deliver 4 additional zero-emission battery-electric buses to CDTA - NFI Group announced that its subsidiary New Flyer of America is currently delivering four zero-emission, battery-electric Xcelsior CHARGE forty-foot heavy-duty transit buses, equipped with next-generation high-energy batteries providing 440kWh of energy to Capital District Transportation Authority, CDTA. The purchase "propels its Strategic Plan and helps the state to reach its goal of transitioning transit fleets to 100% renewable energy by 2035," the company said. CDTA provides transit services to the Capital District of New York, including the counties of Albany, Rensselaer, Saratoga, and Schenectady, and delivers over 16 million passenger trips per year.

07:20 EDT uniQure announces inducement grants under Nasdaq listing rule 5635(c)(4) - uniQure N.V. announced that the Company granted equity awards to 32 newly hired employees as a material inducement to commencing their employment. The equity grants were approved on April 29, 2022 in accordance with Nasdaq Listing Rule 5635(c)(4). In the aggregate, the employees received 84,900 restricted stock units and options to purchase 119,000 ordinary shares of uniQure. Each option has an exercise price of $14.94 per share, the closing price per ordinary share as reported by Nasdaq on the Grant Date. Each option has a ten-year term and will vest over four years from the Grant Date, with 25% of the original number of shares vesting on the first anniversary of the Grant Date and an additional 6.25% of the shares vesting in approximately equal quarterly installments over the twelve successive quarters following the first anniversary of the Grant Date.

07:18 EDT Freyr Battery announces strategic mandates, milestones for next 18 months - FREYR is focused on advancing the following strategic mandates and milestones over the next 18 months: Secure multiple tranches of capital required to fund FREYR's giga scale expansion. FREYR has launched parallel processes with key stakeholders to explore the most capital efficient options to support development of the company's business plan. Finalize additional conditional offtake agreements across the ESS, commercial mobility, and passenger EV market segments to support further capacity expansions. Convert initial two conditional offtake awards to final sales agreements with Honeywell and a global ESS customer. Initiate FREYR's augmented value proposition strategy with the intention to maximize sustainable value creation and enhance the company's competitive position. Key objectives in accordance with this strategy are to continue to evaluate opportunities to diversify FREYR's position across the global battery value chain; and to explore potential partnerships that would enable FREYR to broaden its participation across the battery technology spectrum. Achieve Phase 1 FID on combined Gigafactories 1 & 2 at Mo i Rana upon achievement of commercial, operational, and financing milestones. Proceed to FID on the proposed JV/technology collaboration with Aleees to construct a lithium iron phosphate cathode plant in the Nordic region. The company intends to achieve FID in parallel with FID at combined Gigafactories 1 & 2 at Mo i Rana. Continue to execute FREYR's long-term strategy to establish localized, decarbonized supply chains across the Nordic region and U.S.

07:15 EDT Amryt Pharma announces new patent for Mycapssa - Amryt announces an update regarding the patents for its product Mycapssa. The USPTO has issued to Amryt a notice of allowance for US Patent Application No. 17/094,238, with claims covering the product Mycapssa. This patent will expire in February 2036 and will be listable in the Approved Drug Products with Therapeutic Equivalence Evaluations, published by the FDA. Amryt will have nine Orange Book-listed patents for Mycapssa with patent protection through December 2040. Dr Joe Wiley, CEO of Amryt Pharma, commented: "We are always working to develop and extend our IP portfolio and today's news further illustrates the robust IP protection enjoyed by Mycapssa."

07:14 EDT Gogoro to Launch in Israel summer 2022 - Gogoro is partnering with Metro Motor and Paz Group in Israel to launch its battery swapping platform and Smartscooters in the Tel Aviv metropolitan area this summer and other cities in Israel in the future. Metro Motor is a two-wheel vehicle distributor in Israel and Paz Group is a gas and energy company in Israel. Gogoro Network is a new generation of swappable battery refueling.

07:12 EDT Innoviz Technologies raises forward-looking order book guidance 150% to $6.6B - Currently has 12 prospective customers in RFIs and RFQs stages, up from 10 at last earnings call. Innoviz expects to achieve its stated goal to secure 10 pre-production programs during 2022. To-date the company has secured 9.

07:11 EDT IBM signs Strategic Collaboration Agreement with Amazon Web Services - IBM (IBM) announced that it has signed a Strategic Collaboration Agreement with Amazon Web Services (AMZN) with plans to offer a broad array of its software catalog as Software-as-a-Service on AWS. Building on IBM Software being available as-a-Service on IBM Cloud, this first-of-its-kind agreement between IBM and AWS will provide clients with quick and easy access to IBM Software that spans automation, data and AI, security and sustainability capabilities, is built on Red Hat OpenShift Service on AWS, and runs cloud-native on AWS. The two companies are also committing to a broad range of joint investments to make it easier for clients to consume IBM Software on AWS, including integrated go-to-market activities across sales and marketing, channel incentives, developer enablement and training, and solution development for key verticals and industries such as Oil and Gas, Travel and Transportation, and others.

07:10 EDT Tango Therapeutics sees cash, equivalents funding operations into 2H24

07:09 EDT Kiromic BioPharma to submit amended IND for Procel to FDA in 2H22 - Kiromic BioPharma announces the company will submit an amended Investigational New Drug Application for its first oncology cell therapy candidate Procel directly to the FDA in the second half of 2022. Over the course of the last ten months, the company has developed a solid plan to address the previously outlined chemistry, manufacturing, and control issues cited in the FDA's July 2021 letter regarding the clinical hold on the company's INDs. Based on the unanimous advice from independent regulatory experts, the company has determined that it is not necessary to proceed with the previously contemplated Type A meeting with the FDA to further address the CMC issues and instead will move forward with a submission of an amended IND for Procel directly to the FDA during the second half of this year. The company also announces ongoing progress toward the implementation of a current good manufacturing practice mammalian master cell bank, which will provide a GMP-grade retroviral vector for gamma delta T cell engineering. A cGMP mammalian master cell bank is a significant step forward in the company's clinical pathway and would address a key issue identified by the FDA in the clinical hold letter. "We are very pleased to share these significant regulatory updates, reflecting the progress we have been making as a company. In addition, progress toward establishing the master cell bank will enable us to create the GMP-grade retroviral vector for gamma delta cell engineering - a cornerstone of our clinical program" stated Pietro Bersani, Kiromic BioPharma's CEO. "These achievements demonstrate our team's execution efforts toward our goal of beginning the activation of the clinical trial for our first oncology cell therapy candidate Procel by the end of the fourth quarter of 2022."

07:03 EDT Trevena sees cash, equivalents funding operations into 2023 - Cash and cash equivalents were $48.7 million as of March 31, 2022, which the Company believes will be sufficient to fund the Company's operating expenses and capital expenditure requirements into 2023. This cash balance does not include proceeds from the receipt in April of the first $15 million tranche from the royalty-based financing agreement with an affiliate of R Bridge Healthcare Fund. In addition, the Company announced its Annual General Meeting will be held on June 9th, 2022. In the definitive proxy statements, the Company is requesting approval for additional authorized shares. The proposal would result in no immediate dilution for stockholders. The increase in authorized shares is intended to provide flexibility to execute on the Company's business development opportunities, achieve the $10M tranche from our R-Bridge financing, and advance the Company's products and pipeline.

07:01 EDT Wendy's reports Q1 U.S. same-restaurant sales growth 1.1% - Reports Q1 International same-restaurant sales growth of 14.1%; Global 2.4%.

06:58 EDT Becton Dickinson, Babson expand strategic partnership for blood collection - Babson Diagnostics and BD announced the expansion of a strategic partnership to move blood sample collection into new care settings, including enabling patients to collect blood samples at home for diagnostic testing. Since 2019, the two companies have collaborated to create a capillary blood collection and testing system, now in advanced development, to enable laboratory-quality, small-volume capillary blood collection at retail settings by team members with no previous experience in blood collection. Plans under the expanded agreement include continuing research and development to enable self-collection, mobile services and at-home collection. Babson and BD also will expand the types of blood tests that are possible through small-volume blood collection beyond primary care-oriented tests, and they also plan to develop diagnostic tests for pediatric use. Over this long-term collaboration, Babson and BD are advancing development of the blood testing ecosystem, which includes BD's next generation capillary collection technology and Babson's proprietary automated sample-handling and analytical technologies. These have been designed to work together to enable blood testing that requires only one-tenth the sample volume of traditional venipuncture methods without sacrificing quality, accuracy, or the number and types of tests that are possible.

06:56 EDT Aecom-led JV awarded IDIQ contract with $400M ceiling - Aecom announced its Resolution Consultants joint venture with EnSafe has been awarded a single-award, indefinite-delivery, indefinite-quantity contract by the Naval Facilities Engineering Systems Command Atlantic to deliver architecture and engineering services for the Comprehensive Long-Term Environmental Action Navy program. Under the contract with a $400M ceiling, the joint venture will perform environmental studies, investigations, and designs that address pressing environmental challenges.

06:50 EDT View Inc. to delay filing 10-Q for Q1 - In a regulatory filing, the company states: "View, Inc. is unable, without unreasonable effort or expense, to file its Quarterly Report on Form 10-Q for the period ended March 31, 2022, within the prescribed time period for the reasons described below. On November 9, 2021, the Company filed a Current Report on Form 8-K disclosing, among other things, that the Audit Committee of the Company's Board of Directors had substantially completed an independent investigation focusing on the adequacy of the Company's previously reported warranty accrual. While the Audit Committee investigation is now complete, the Company has not been able to finalize its financial statements or corresponding assessment of the effectiveness of its disclosure controls and procedures and internal control over financial reporting. The Company is also unable to make a reasonable estimate of changes in results of operations in its financial statements at this time; however, management anticipates that they will be disclosing substantial doubt about the Company's ability to continue as a going concern, as the Company does not currently have adequate financial resources to fund its forecasted operating costs and meet its obligations for at least twelve months from the expected issuance date of the 2021 Annual Report on Form 10-K. While management will look to raise capital, there can be no assurance that the necessary financing will be available or will be available on terms acceptable to the Company. Given the findings of its Audit Committee, the Company also expects to report additional material weaknesses, and is working to determine any additional adjustments to the Company's financial statements that may be required."

06:48 EDT FDA approves Lilly, Incyte's OLUMIANT for the treatment of COVID-19 - Eli Lilly and Company (LLY) and Incyte (INCY) announced the U.S. Food and Drug Administration has approved OLUMIANT for the treatment of COVID-19 in hospitalized adults requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation with a recommended dose of 4-mg once daily for 14 days or until hospital discharge, whichever comes first. The FDA's approval is supported by results from two randomized, double-blind, placebo-controlled Phase 3 studies, announced previously. No new safety signals potentially related to the use of OLUMIANT were identified in the studies. Baricitinib has been available in the U.S. under Emergency Use Authorization since November 2020. An EUA will remain in place for hospitalized pediatric patients 2 to less than 18 years old who require various degrees of oxygen support. The emergency authorization is not an approval and is temporary for the duration where circumstances justify the authorization. For additional information about the authorized use, please see the FDA Letter of Authorization, Fact Sheet for Healthcare Providers and Fact Sheet for Patients, Parents and Caregivers. Lilly has submitted applications for regulatory approval or authorization to multiple regulatory agencies around the world and anticipates further regulatory decisions to follow. The U.S. FDA-approved labeling for OLUMIANT carries a boxed warning for risk of serious infections, mortality, malignancy, major adverse cardiovascular events and thrombosis. Patients treated with OLUMIANT are at an increased risk of serious bacterial, fungal, viral and opportunistic infections leading to hospitalization or death, including tuberculosis. Higher rates of all-cause mortality and MACE have been observed with another JAK inhibitor versus tumor necrosis factor blockers. Malignancies and thrombosis have occurred in patients treated with OLUMIANT and higher rates of each have been observed with another JAK inhibitor versus TNF blockers. Consider the risks and benefits of treatment prior to initiating or continuing therapy with OLUMIANT. Please see additional Important Safety Information below. OLUMIANT is a once-daily, oral JAK inhibitor discovered by Incyte and licensed to Lilly. To learn more about OLUMIANT, please visit www.OLUMIANT.com. OLUMIANT is available in the U.S. as 1-mg and 2-mg tablets through Lilly's authorized specialty distributors.

06:44 EDT IRD awarded C$1.2M weigh-in-motion project for Illinois tollway - International Road Dynamics, a Quarterhill company, announced that the company has been awarded two contracts totalling C$1.2M for Weigh-In-Motion system upgrades for the Illinois State Toll Highway Authority. The new sites will be used by the Illinois State Police to monitor commercial vehicles for weight and tire violations. The upgrade project includes the removal of existing WIM Systems on I-94 and I-355, installation of new Virtual Weigh-In-Motion sites comprising WIM sensors, iSINC WIM controllers, cameras, over-height detection sensors, and Tire Anomaly and Classification Systems. The WIM sensors will be used to screen for overweight vehicles and the TACS systems will identify vehicles that are unsafe due to flat, missing, mismatched, or underinflated tires.

06:37 EDT Flowserve valves selected by chemical recycling plant in Austria - Flowserve was awarded a contract to provide control and ball valves to OMV's chemical recycling demonstration plant in the city of Schwechat, Austria, located approximately 16 km southeast of Vienna. The OMV demonstration plant will employ their patented ReOil technology to convert plastic waste into synthetic feedstock, which can then be used to produce base chemicals and plastics for all types of applications, including packaging for food industry and medical products. The facility is expected to be in operation in 2023. Based on the results of this demonstration plant, OMV will implement a permanent, industrial-scale plant with operations planned for 2026.

06:34 EDT J&J appoints Thibaut Mongon as CEO Designate of new consumer health company - Johnson & Johnson announced the appointment of Thibaut Mongon as CEO Designate and Paul Ruh as CFO Designate of the future, listed New Consumer Health Company. The company said, "As announced in November 2021, the planned separation would create two global leaders - the new Johnson & Johnson and the New Consumer Health Company - that are better positioned to deliver improved health outcomes for patients and consumers through innovation, pursue more targeted business strategies and accelerate growth.: This leadership transition will occur upon completion of the planned separation of the Consumer Health business, expected to occur within 2023, subject to legal requirements including consultation with works councils and employee representatives, as required. Directors and additional executive leadership appointments will be determined in the coming months as the planned separation process progresses. A business leader with more than 20 years of global experience at Johnson & Johnson, Thibaut Mongon has served as Executive Vice President and Worldwide Chairman of Consumer Health at Johnson & Johnson since 2019. Ruh joined Johnson & Johnson five years ago to become the CFO of the Consumer Health business

06:26 EDT Shenandoah to expand Glo Fiber fiber-optic network in Virginia - Glo Fiber, powered by Shenandoah Telecommunications Company, announced that construction of their all-fiber network will begin late this summer in the Rockingham County, Virginia towns of Broadway, Bridgewater, Dayton, Grottoes, Timberville, and Elkton. The company will launch services in late 2022, offering blazing fast internet to more than 8,000 homes and businesses by mid-2023. Glo Fiber delivers future-proof fiber-to-the-premises internet access and phone service in the Mid-Atlantic region, with optional wall-to-wall Wi-Fi service that allows customers to connect anywhere in their home or business. Using Wi-Fi 6 technology, customers can enjoy faster speeds, higher performance, and better support for multiple devices throughout the home with the assurance of advanced protection and automatic updates.

06:21 EDT NuZee enters manufacturing agreement with Tennessee partner facility - NuZee announced that it has entered into a manufacturing agreement with a partner facility in Knoxville, Tennessee and is expanding its manufacturing footprint to the Eastern United States. With this partnership, NuZee expects to offer a holistic coffee supply and manufacturing program to its existing and new customers. These services may include coffee roasting and non-single serve coffee product co-packing, in addition to the single serve coffee formats NuZee manufactures today. This facility is SQF and Organic certified.

06:17 EDT KBR awarded green ammonia contract from JGC Holdings Corporation - KBR (KBR) announced that it was awarded a contract for its green ammonia technology, K-GreeN, from JGC Holdings Corporation (JGCCY) for a project sponsored by New Energy and Industrial Technology Development Organization, a national research and development agency in Japan. Under the terms of the contract, KBR will provide technology licensing and basic engineering for a pilot project under NEDO's Green Innovation Fund in Fukushima, Japan.

06:09 EDT Eqonex appoints Daniel Lang as CFO - EQONEX announced the appointment of Daniel Ling as CFO and Member of the Executive Committee, effective immediately. Daniel was recently appointed to the EQONEX Board of Directors as part of the Company's strategic partnership with Bifinity UAB, a payments technology company. Concurrently, Paul Ewing, the Company's previous CFO, has been appointed as COO, effective immediately. Andrew Eldon resigned from his position as COO to pursue other opportunities. Under the terms of the strategic partnership announced in early March 2022, Bifinity has the right to nominate key management positions and Board members. Jonathan Farnell, EQONEX CEO and Almira Cemmell, EQONEX Chief Corporate Affairs Officer were previously appointed to the management team. Prior to joining EQONEX, Daniel served as the Director of Strategy for Bifinity UAB.

05:57 EDT The9, SolarCoin sign contract on purchase of block chain computing center - The9 Limited announced that its wholly-owned subsidiary NBTC Limited and Kyrgyzstan enterprise SolarCoin, have signed a Purchase Agreement regarding a block chain computing center in Kyrgyzstan, pursuant to which The9 will obtain 31.5MW electricity capacity for the deployment of its 7,500 Antminer S19J Bitcoin mining machines contributing approximately 675PH/s hash power. The parties are looking forward to complete the construction work and have the computing center powered on around the end of July 2022. The expected electricity cost of the computing center is $0.05/kWh. According to the Agreement, The9 will acquire the ownership of transformers with a capacity of 31.5 MW along with the supporting low voltage equipment, plant and its internal supporting facilities, network equipment as well as the right to use the high voltage equipment and land in perpetuity.

05:56 EDT Occidental Petroleum sees FY22 oil & gas production 1,140-1,170 Mboed

05:55 EDT Natuzzi signs partnership agreement with Truong Thanh Furniture - To accelerate the commercial expansion in the rest of APAC region, Natuzzi S.p.A. signed a partnership with Truong Thanh Furniture Corporation, a listed company in the furniture sector, located in Vietnam. TTF is already an active partner of Natuzzi to produce upholstery in Vietnam for the North American market. TTF in addition plays a key role in the production of furniture for leading furniture names in the USA. Following the finalization of this partnership, TTF acquired a 20% stake in Natuzzi Singapore PTE. LTD, a controlled subsidiary of Natuzzi S.p.A., for a total cash consideration of $5.4M already paid in favor of Natuzzi Singapore. As a result, Natuzzi S.p.A. currently owns 74.4% of Natuzzi Singapore, whereas the other minority shareholder, Richard Tan, owns 5.6% of the share capital. In addition, Natuzzi S.p.A. maintains the majority of the board of Natuzzi Singapore. The partnership in Natuzzi Singapore will aim at fostering the commercial development both in the branded retail and in the contract business, as well as strengthening its industrial platform.

05:51 EDT BlackBerry partners with Midas Group to expand its go-to-market sales motion - BlackBerry announced that it has entered into a partnership with Midis Group to expand its go-to-market sales motion across Eastern Europe, the Middle East, and Africa. A technology company, with a network of over 170 affiliates and partners across these markets, Midis Group will focus on driving growth for BlackBerry's Cybersecurity business unit. Midis Group will leverage its on-the-ground expertise, market knowledge, and regional infrastructure to establish BlackBerry-branded local offices focused on representing BlackBerry's comprehensive portfolio of unified endpoint management solutions and next-generation, AI-based Cylance cybersecurity products.

05:00 EDT Roche says Phase III lung cancer study did not met co-primary endpoint - Roche announced results from its Phase III SKYSCRAPER-01 study, evaluating the investigational anti-TIGIT immunotherapy tiragolumab plus Tecentriq versus Tecentriq alone as an initial treatment for people with PD-L1-high locally advanced or metastatic non-small cell lung cancer. The study did not meet its co-primary endpoint of progression-free survival. At this first analysis, the other co-primary endpoint of overall survival was immature, and the study will continue until the next planned analysis, Roche said in a statement. A numerical improvement was observed in both co-primary endpoints. Data suggest that tiragolumab plus Tecentriq was well-tolerated and no new safety signals were identified when adding tiragolumab, it added. "While these results are not what we hoped for in our first analysis, we look forward to seeing mature overall survival for this study to determine next steps," said Levi Garraway, Roche's Chief Medical Officer and Head of Global Product Development. "We continue to believe that TIGIT may have a role in cancer treatment and we will share additional results from our tiragolumab programme as they emerge."